WO2024086595A2 - Systems and methods for gene therapy - Google Patents
Systems and methods for gene therapy Download PDFInfo
- Publication number
- WO2024086595A2 WO2024086595A2 PCT/US2023/077110 US2023077110W WO2024086595A2 WO 2024086595 A2 WO2024086595 A2 WO 2024086595A2 US 2023077110 W US2023077110 W US 2023077110W WO 2024086595 A2 WO2024086595 A2 WO 2024086595A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- vector
- cell population
- target
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 184
- 238000001415 gene therapy Methods 0.000 title claims abstract description 36
- 239000013598 vector Substances 0.000 claims abstract description 116
- 230000005291 magnetic effect Effects 0.000 claims abstract description 74
- 239000011324 bead Substances 0.000 claims abstract description 54
- 239000002245 particle Substances 0.000 claims abstract description 44
- 238000010361 transduction Methods 0.000 claims abstract description 37
- 238000004519 manufacturing process Methods 0.000 claims abstract description 36
- 230000026683 transduction Effects 0.000 claims abstract description 35
- 208000015181 infectious disease Diseases 0.000 claims abstract description 26
- 230000002458 infectious effect Effects 0.000 claims abstract description 19
- 238000002512 chemotherapy Methods 0.000 claims abstract description 13
- 102000004127 Cytokines Human genes 0.000 claims abstract description 9
- 108090000695 Cytokines Proteins 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 358
- 210000000130 stem cell Anatomy 0.000 claims description 35
- 210000004369 blood Anatomy 0.000 claims description 22
- 239000008280 blood Substances 0.000 claims description 22
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 230000002463 transducing effect Effects 0.000 claims description 20
- 239000013603 viral vector Substances 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 12
- 210000002865 immune cell Anatomy 0.000 claims description 11
- 210000001185 bone marrow Anatomy 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 230000036512 infertility Effects 0.000 claims description 6
- 230000008520 organization Effects 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 230000001483 mobilizing effect Effects 0.000 claims description 5
- 238000012429 release testing Methods 0.000 claims description 5
- 238000003306 harvesting Methods 0.000 claims description 4
- 238000003032 molecular docking Methods 0.000 claims description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 description 81
- -1 SCF Proteins 0.000 description 38
- 239000000047 product Substances 0.000 description 29
- 239000006249 magnetic particle Substances 0.000 description 26
- 230000001225 therapeutic effect Effects 0.000 description 26
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 23
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 23
- 102000036693 Thrombopoietin Human genes 0.000 description 23
- 108010041111 Thrombopoietin Proteins 0.000 description 23
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 21
- 150000007523 nucleic acids Chemical class 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 238000011282 treatment Methods 0.000 description 21
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 20
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 20
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 20
- 108700014844 flt3 ligand Proteins 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 18
- 241000725303 Human immunodeficiency virus Species 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 239000011886 peripheral blood Substances 0.000 description 16
- 210000005259 peripheral blood Anatomy 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 14
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 12
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 12
- 239000003114 blood coagulation factor Substances 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 241000713666 Lentivirus Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229910052742 iron Inorganic materials 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- YURDCJXYOLERLO-LCYFTJDESA-N (2E)-5-methyl-2-phenylhex-2-enal Chemical compound CC(C)C\C=C(\C=O)C1=CC=CC=C1 YURDCJXYOLERLO-LCYFTJDESA-N 0.000 description 9
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 9
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 239000005090 green fluorescent protein Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 108010070047 Notch Receptors Proteins 0.000 description 8
- 102000005650 Notch Receptors Human genes 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 102000055151 human KITLG Human genes 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 229920002873 Polyethylenimine Polymers 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108010002386 Interleukin-3 Proteins 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 230000015271 coagulation Effects 0.000 description 6
- 238000005345 coagulation Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 150000004679 hydroxides Chemical class 0.000 description 6
- 229940100601 interleukin-6 Drugs 0.000 description 6
- 235000013980 iron oxide Nutrition 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 229920001059 synthetic polymer Polymers 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 5
- 102100039064 Interleukin-3 Human genes 0.000 description 5
- 108010001831 LDL receptors Proteins 0.000 description 5
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 5
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 102000015215 Stem Cell Factor Human genes 0.000 description 5
- 108010039445 Stem Cell Factor Proteins 0.000 description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
- 238000002617 apheresis Methods 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 208000000509 infertility Diseases 0.000 description 5
- 208000021267 infertility disease Diseases 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 229940076264 interleukin-3 Drugs 0.000 description 5
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000001177 retroviral effect Effects 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000009410 Chemokine receptor Human genes 0.000 description 4
- 108050000299 Chemokine receptor Proteins 0.000 description 4
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 4
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241001663880 Gammaretrovirus Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102000003815 Interleukin-11 Human genes 0.000 description 4
- 108090000177 Interleukin-11 Proteins 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- 102000000704 Interleukin-7 Human genes 0.000 description 4
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000713311 Simian immunodeficiency virus Species 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229940074383 interleukin-11 Drugs 0.000 description 4
- 229940100994 interleukin-7 Drugs 0.000 description 4
- 235000014413 iron hydroxide Nutrition 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 3
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 3
- 102100022749 Aminopeptidase N Human genes 0.000 description 3
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 3
- 102100037917 CD109 antigen Human genes 0.000 description 3
- 102100024210 CD166 antigen Human genes 0.000 description 3
- 102100022002 CD59 glycoprotein Human genes 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 241000501789 Cocal virus Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 201000004939 Fanconi anemia Diseases 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 3
- 101000738399 Homo sapiens CD109 antigen Proteins 0.000 description 3
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 3
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 3
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 3
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- 102100039564 Leukosialin Human genes 0.000 description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
- 208000015439 Lysosomal storage disease Diseases 0.000 description 3
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 3
- 241000714177 Murine leukemia virus Species 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 102100040120 Prominin-1 Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 3
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000005672 electromagnetic field Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 3
- 229960002169 plerixafor Drugs 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000003319 supportive effect Effects 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- DKVDSNMJXDQNCD-UHFFFAOYSA-N 1h-pyrrolo[2,3-f]quinazoline Chemical class N1=CN=CC2=C(NC=C3)C3=CC=C21 DKVDSNMJXDQNCD-UHFFFAOYSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 2
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 2
- 102100026792 Aryl hydrocarbon receptor Human genes 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 229940122444 Chemokine receptor antagonist Drugs 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- QXKAIJAYHKCRRA-JJYYJPOSSA-N D-arabinonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(O)=O QXKAIJAYHKCRRA-JJYYJPOSSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- 208000032003 Glycogen storage disease due to glucose-6-phosphatase deficiency Diseases 0.000 description 2
- 206010018464 Glycogen storage disease type I Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000962530 Homo sapiens Hyaluronidase-1 Proteins 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000836873 Homo sapiens Nucleotide exchange factor SIL1 Proteins 0.000 description 2
- 101000712958 Homo sapiens Ras association domain-containing protein 1 Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 241000713673 Human foamy virus Species 0.000 description 2
- 241000714192 Human spumaretrovirus Species 0.000 description 2
- 102100039283 Hyaluronidase-1 Human genes 0.000 description 2
- 102100032816 Integrin alpha-6 Human genes 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102100035488 Nectin-2 Human genes 0.000 description 2
- 102100027096 Nucleotide exchange factor SIL1 Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920000805 Polyaspartic acid Polymers 0.000 description 2
- 102100033243 Ras association domain-containing protein 1 Human genes 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 102100035712 Serrate RNA effector molecule homolog Human genes 0.000 description 2
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 101000880156 Streptomyces cacaoi Subtilisin inhibitor-like protein 1 Proteins 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- 208000002903 Thalassemia Diseases 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000009141 biological interaction Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- AIXMJTYHQHQJLU-UHFFFAOYSA-N chembl210858 Chemical compound O1C(CC(=O)OC)CC(C=2C=CC(O)=CC=2)=N1 AIXMJTYHQHQJLU-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002559 chemokine receptor antagonist Substances 0.000 description 2
- 208000016532 chronic granulomatous disease Diseases 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 201000004541 glycogen storage disease I Diseases 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- SIBCJMZHJZDUNK-UHFFFAOYSA-N methyl 4-(3-piperidin-1-ylpropylamino)-9h-pyrimido[4,5-b]indole-7-carboxylate Chemical compound C=1C(C(=O)OC)=CC=C(C=23)C=1NC3=NC=NC=2NCCCN1CCCCC1 SIBCJMZHJZDUNK-UHFFFAOYSA-N 0.000 description 2
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 description 2
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 description 2
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229920000447 polyanionic polymer Polymers 0.000 description 2
- 108010064470 polyaspartate Proteins 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- ZPEFMSTTZXJOTM-OULXEKPRSA-N (1R,2S)-tranylcypromine hydrochloride Chemical compound Cl.N[C@@H]1C[C@H]1C1=CC=CC=C1 ZPEFMSTTZXJOTM-OULXEKPRSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ICGQLNMKJVHCIR-UHFFFAOYSA-N 1,3,2-dioxazetidin-4-one Chemical compound O=C1ONO1 ICGQLNMKJVHCIR-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 102100031599 2-(3-amino-3-carboxypropyl)histidine synthase subunit 1 Human genes 0.000 description 1
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 1
- GHJBVXMGYKPTFO-UHFFFAOYSA-N 2-phenylpyrazole-3-carboxamide Chemical compound NC(=O)C1=CC=NN1C1=CC=CC=C1 GHJBVXMGYKPTFO-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100035028 Alpha-L-iduronidase Human genes 0.000 description 1
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 101100449747 Aneurinibacillus migulanus gsp gene Proteins 0.000 description 1
- 102000006501 Angiopoietin-like Proteins Human genes 0.000 description 1
- 108010019425 Angiopoietin-like Proteins Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 101100281515 Arabidopsis thaliana FOX1 gene Proteins 0.000 description 1
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 102100022146 Arylsulfatase A Human genes 0.000 description 1
- 102100031491 Arylsulfatase B Human genes 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102100026031 Beta-glucuronidase Human genes 0.000 description 1
- 102100037674 Bis(5'-adenosyl)-triphosphatase Human genes 0.000 description 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
- 101100064718 Borrelia bavariensis (strain ATCC BAA-2496 / DSM 23469 / PBi) fusA1 gene Proteins 0.000 description 1
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 108010049990 CD13 Antigens Proteins 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101150053778 CSF1R gene Proteins 0.000 description 1
- 108010086884 CTCE-0021 Proteins 0.000 description 1
- 108010048913 CTCE-0214 Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101150110592 CTS1 gene Proteins 0.000 description 1
- 101100209555 Caenorhabditis elegans vha-17 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 206010062759 Congenital dyskeratosis Diseases 0.000 description 1
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 1
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 1
- 102100028233 Coronin-1A Human genes 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010076010 Cystathionine beta-lyase Proteins 0.000 description 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100261976 Drosophila melanogaster trk gene Proteins 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 102100035813 E3 ubiquitin-protein ligase CBL Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 102100022207 E3 ubiquitin-protein ligase parkin Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical group ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102100029951 Estrogen receptor beta Human genes 0.000 description 1
- 101710196289 Eukaryotic translation initiation factor 2-alpha kinase 1 Proteins 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 101150081880 FGF1 gene Proteins 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000714174 Feline sarcoma virus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 102100023416 G-protein coupled receptor 15 Human genes 0.000 description 1
- 102100022360 GATOR complex protein NPRL2 Human genes 0.000 description 1
- 101150000435 GSS gene Proteins 0.000 description 1
- 102100037948 GTP-binding protein Di-Ras3 Human genes 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000495 Glia Maturation Factor Proteins 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241001123589 Gorilla papillomavirus Species 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 102100031249 H/ACA ribonucleoprotein complex subunit DKC1 Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 102100039991 Heparan-alpha-glucosaminide N-acetyltransferase Human genes 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 1
- 101000866191 Homo sapiens 2-(3-amino-3-carboxypropyl)histidine synthase subunit 1 Proteins 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101000923070 Homo sapiens Arylsulfatase B Proteins 0.000 description 1
- 101000765010 Homo sapiens Beta-galactosidase Proteins 0.000 description 1
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 description 1
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 1
- 101000829794 Homo sapiens G-protein coupled receptor 15 Proteins 0.000 description 1
- 101000951235 Homo sapiens GTP-binding protein Di-Ras3 Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000844866 Homo sapiens H/ACA ribonucleoprotein complex subunit DKC1 Proteins 0.000 description 1
- 101001035092 Homo sapiens Heparan-alpha-glucosaminide N-acetyltransferase Proteins 0.000 description 1
- 101000898505 Homo sapiens Histatin-3 Proteins 0.000 description 1
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 description 1
- 101000962526 Homo sapiens Hyaluronidase-2 Proteins 0.000 description 1
- 101000840540 Homo sapiens Iduronate 2-sulfatase Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101001066305 Homo sapiens N-acetylgalactosamine-6-sulfatase Proteins 0.000 description 1
- 101000829992 Homo sapiens N-acetylglucosamine-6-sulfatase Proteins 0.000 description 1
- 101000651201 Homo sapiens N-sulphoglucosamine sulphohydrolase Proteins 0.000 description 1
- 101000998623 Homo sapiens NADH-cytochrome b5 reductase 3 Proteins 0.000 description 1
- 101000801640 Homo sapiens Phospholipid-transporting ATPase ABCA3 Proteins 0.000 description 1
- 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 1
- 101000617546 Homo sapiens Presenilin-2 Proteins 0.000 description 1
- 101000738940 Homo sapiens Proline-rich nuclear receptor coactivator 1 Proteins 0.000 description 1
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 description 1
- 101000898093 Homo sapiens Protein C-ets-2 Proteins 0.000 description 1
- 101000585703 Homo sapiens Protein L-Myc Proteins 0.000 description 1
- 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 description 1
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 description 1
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
- 101001061518 Homo sapiens RNA-binding protein FUS Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000632270 Homo sapiens Semaphorin-3B Proteins 0.000 description 1
- 101000605835 Homo sapiens Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 description 1
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 1
- 101000891113 Homo sapiens T-cell acute lymphocytic leukemia protein 1 Proteins 0.000 description 1
- 101000800488 Homo sapiens T-cell leukemia homeobox protein 1 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000800312 Homo sapiens TERF1-interacting nuclear factor 2 Proteins 0.000 description 1
- 101000837626 Homo sapiens Thyroid hormone receptor alpha Proteins 0.000 description 1
- 101000813738 Homo sapiens Transcription factor ETV6 Proteins 0.000 description 1
- 101000636213 Homo sapiens Transcriptional activator Myb Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000659267 Homo sapiens Tumor suppressor candidate 2 Proteins 0.000 description 1
- 101000912503 Homo sapiens Tyrosine-protein kinase Fgr Proteins 0.000 description 1
- 101001022129 Homo sapiens Tyrosine-protein kinase Fyn Proteins 0.000 description 1
- 101001054878 Homo sapiens Tyrosine-protein kinase Lyn Proteins 0.000 description 1
- 101001135589 Homo sapiens Tyrosine-protein phosphatase non-receptor type 22 Proteins 0.000 description 1
- 101000740759 Homo sapiens Voltage-dependent calcium channel subunit alpha-2/delta-2 Proteins 0.000 description 1
- 241000701190 Human adenovirus 11 Species 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102100039285 Hyaluronidase-2 Human genes 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 102100031612 Hypermethylated in cancer 1 protein Human genes 0.000 description 1
- 101710133850 Hypermethylated in cancer 1 protein Proteins 0.000 description 1
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 description 1
- 108010003381 Iduronidase Proteins 0.000 description 1
- 102000004627 Iduronidase Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090000191 Inhibitor of growth protein 1 Proteins 0.000 description 1
- 102000003781 Inhibitor of growth protein 1 Human genes 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000004289 Interferon regulatory factor 1 Human genes 0.000 description 1
- 108090000890 Interferon regulatory factor 1 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000002297 Laminin Receptors Human genes 0.000 description 1
- 108010000851 Laminin Receptors Proteins 0.000 description 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 1
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 102100031955 Lon protease homolog, mitochondrial Human genes 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- 108700012912 MYCN Proteins 0.000 description 1
- 101150022024 MYCN gene Proteins 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102100039373 Membrane cofactor protein Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 206010028095 Mucopolysaccharidosis IV Diseases 0.000 description 1
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 description 1
- 208000025915 Mucopolysaccharidosis type 6 Diseases 0.000 description 1
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
- 101100001703 Mus musculus Angptl2 gene Proteins 0.000 description 1
- 101100001705 Mus musculus Angptl3 gene Proteins 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 101100240347 Mus musculus Nectin2 gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 241000608621 Myotis lucifugus Species 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 description 1
- 102100023282 N-acetylglucosamine-6-sulfatase Human genes 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 description 1
- 102100033153 NADH-cytochrome b5 reductase 3 Human genes 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102100023064 Nectin-1 Human genes 0.000 description 1
- 101710043845 Nectin-1 Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 101100462611 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) prr-1 gene Proteins 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 101150074217 Nprl2 gene Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 241000276569 Oryzias latipes Species 0.000 description 1
- 240000007019 Oxalis corniculata Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102100037499 Parkinson disease protein 7 Human genes 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 102100033623 Phospholipid-transporting ATPase ABCA3 Human genes 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 102100022033 Presenilin-1 Human genes 0.000 description 1
- 102100022036 Presenilin-2 Human genes 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102100031952 Protein 4.1 Human genes 0.000 description 1
- 101710196266 Protein 4.1 Proteins 0.000 description 1
- 102100035251 Protein C-ets-1 Human genes 0.000 description 1
- 102100021890 Protein C-ets-2 Human genes 0.000 description 1
- 108010032428 Protein Deglycase DJ-1 Proteins 0.000 description 1
- 102100030128 Protein L-Myc Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 102100028588 Protein ZNRD2 Human genes 0.000 description 1
- 241000709748 Pseudomonas phage PRR1 Species 0.000 description 1
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 description 1
- 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108700014121 Pyruvate Kinase Deficiency of Red Cells Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
- 102100028469 RNA-binding protein FUS Human genes 0.000 description 1
- 108090000292 RNA-binding protein FUS Proteins 0.000 description 1
- 102000003890 RNA-binding protein FUS Human genes 0.000 description 1
- 241000270942 Rana pipiens Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100517381 Rattus norvegicus Ntrk1 gene Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000712909 Reticuloendotheliosis virus Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 101150019443 SMAD4 gene Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 101000702553 Schistosoma mansoni Antigen Sm21.7 Proteins 0.000 description 1
- 101000714192 Schistosoma mansoni Tegument antigen Proteins 0.000 description 1
- 101100537955 Schizosaccharomyces pombe (strain 972 / ATCC 24843) trk1 gene Proteins 0.000 description 1
- 102100027979 Semaphorin-3B Human genes 0.000 description 1
- 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 description 1
- 208000000859 Sickle cell trait Diseases 0.000 description 1
- 201000001828 Sly syndrome Diseases 0.000 description 1
- 108700032504 Smad2 Proteins 0.000 description 1
- 101150102611 Smad2 gene Proteins 0.000 description 1
- 108700031298 Smad4 Proteins 0.000 description 1
- 241000692850 Sophora cassioides Species 0.000 description 1
- 102100032889 Sortilin Human genes 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100040365 T-cell acute lymphocytic leukemia protein 1 Human genes 0.000 description 1
- 102100033111 T-cell leukemia homeobox protein 1 Human genes 0.000 description 1
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 1
- 101150014554 TARDBP gene Proteins 0.000 description 1
- 102100033085 TERF1-interacting nuclear factor 2 Human genes 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102100028702 Thyroid hormone receptor alpha Human genes 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 1
- 102100039580 Transcription factor ETV6 Human genes 0.000 description 1
- 102100030780 Transcriptional activator Myb Human genes 0.000 description 1
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 description 1
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 description 1
- 241000254113 Tribolium castaneum Species 0.000 description 1
- 108010091356 Tumor Protein p73 Proteins 0.000 description 1
- 102000018252 Tumor Protein p73 Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100035221 Tyrosine-protein kinase Fyn Human genes 0.000 description 1
- 102100026857 Tyrosine-protein kinase Lyn Human genes 0.000 description 1
- 102100033138 Tyrosine-protein phosphatase non-receptor type 22 Human genes 0.000 description 1
- 101710173440 Ubiquilin-2 Proteins 0.000 description 1
- 102100039933 Ubiquilin-2 Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 102100037058 Voltage-dependent calcium channel subunit alpha-2/delta-2 Human genes 0.000 description 1
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 description 1
- 241000238118 Xanthidae Species 0.000 description 1
- ADIGAFWLDDSRAG-UHFFFAOYSA-N [ClH]1[ClH]N=NN=C1 Chemical compound [ClH]1[ClH]N=NN=C1 ADIGAFWLDDSRAG-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 201000006486 beta-mannosidosis Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 108010005713 bis(5'-adenosyl)triphosphatase Proteins 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- RAURUSFBVQLAPW-DNIKMYEQSA-N clocinnamox Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)NC(=O)\C=C\C=2C=CC(Cl)=CC=2)CC1)O)CC1CC1 RAURUSFBVQLAPW-DNIKMYEQSA-N 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229940105774 coagulation factor ix Drugs 0.000 description 1
- 229940105778 coagulation factor viii Drugs 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- FNFMQIWXTYFRKA-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1[CH]CC(N)CC1 FNFMQIWXTYFRKA-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 101150060629 def gene Proteins 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000009356 dyskeratosis congenita Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000005293 ferrimagnetic effect Effects 0.000 description 1
- 239000002902 ferrimagnetic material Substances 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 229940029303 fibroblast growth factor-1 Drugs 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940009600 gammagard Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 102000003898 interleukin-24 Human genes 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000002273 mucopolysaccharidosis II Diseases 0.000 description 1
- 208000005340 mucopolysaccharidosis III Diseases 0.000 description 1
- 208000000690 mucopolysaccharidosis VI Diseases 0.000 description 1
- 208000010978 mucopolysaccharidosis type 4 Diseases 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- ABXIUYMKZDZUDC-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-2-(5-methylpyridin-3-yl)-9-propan-2-ylpurin-6-amine Chemical compound N1=C2N(C(C)C)C=NC2=C(NCCC=2C3=CC=CC=C3NC=2)N=C1C1=CN=CC(C)=C1 ABXIUYMKZDZUDC-UHFFFAOYSA-N 0.000 description 1
- 210000004296 naive t lymphocyte Anatomy 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940081858 plasmalyte a Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- KNVAYBMMCPLDOZ-UHFFFAOYSA-N propan-2-yl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OC(C)C KNVAYBMMCPLDOZ-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 108020003519 protein disulfide isomerase Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 241001507086 salmonid fish Species 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 108010057210 telomerase RNA Proteins 0.000 description 1
- 230000033863 telomere maintenance Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N γ Benzene hexachloride Chemical compound ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
- 229910006297 γ-Fe2O3 Inorganic materials 0.000 description 1
Definitions
- the current disclosure describes systems and methods to simplify gene therapy.
- the present disclosure provides a method of manufacturing cells ex vivo using magnetic field transfection.
- the present disclosure also provides a method of treating a subject in need thereof with the manufactured cells and a system that can be added to a cell collection and/or manufacturing system to perform the methods disclosed herein.
- Lentiviral vector gene therapy delivered to blood cells such as stem cells has dramatically improved the outcome and quality of life for persons diagnosed with genetic, malignant, and infectious diseases that affect tens of millions of patients worldwide.
- Current state of the art methods of ex vivo gene therapy require the collection of a stem cell mobilized apheresis product from a patient, followed by initial platelet and plasma washing, then purification of rare blood stem cells (CD34+) via immunomagnetic beads and a magnetic field in which bead-bound cells are retained. Once desired CD34+ cells are purified, they are stimulated in culture conditions which require specialized media and supplements. Then lentivirus vector supernatants are added for transduction over days.
- transduced cells are washed to remove any unused virus, and formulated for release testing, storage, and infusion into the patient. This process requires 3-4 days of manufacturing time in an International Standards Organization (ISO) class 5 clean room to maintain product sterility and quality.
- ISO International Standards Organization
- the simplified workflow is accomplished by enriching and transducing target cells by performing magnetic-bead-based enrichment and magnetically-assisted viral transduction (MAT), sequentially or simultaneously.
- MAT magnetic-bead-based enrichment and magnetically-assisted viral transduction
- the simplified workflow includes obtaining a cell population including target cells, exposing the cell population to target-cell enriching magnetic beads, contacting the cell population with vector-magnetic bead complexes, and/or applying a magnetic field to the cell population during transduction. The exposing, contacting, and applying may be applied simultaneously or sequentially.
- the cell population is exposed to target-cell-enriching magnetic beads prior to contacting the cell population with vector-magnetic bead complexes and/or applying a magnetic field to the cell population during transduction.
- the vector is a lentiviral vector.
- the method further includes formulating a cell product for administration to a subject.
- the method further includes evaluating the quality and sterility of the cell product.
- target cells can be simultaneously enriched and transduced.
- the present disclosure further describes a method of treating a subject in need of gene therapy.
- the method of treating the subject includes collecting a cell population from the subject wherein the cell population includes target cells, enriching stem cells from the rest of the cell population with target-cell enriching magnetic beads, transducing target cells with vector- magnetic bead complexes, applying a magnetic field to the cell population, and formulating and administering transduced target cells to the subject.
- the method of treating further includes, harvesting and washing transduced target cells, performing release testing of transduced target cells, and/or administering a mobilizing agent to the subject prior to collection of the cell population.
- the subject does not receive chemotherapy or other cell suppressive treatments between the collecting and the administering.
- the subject does not receive chemotherapy or other cell suppressive treatments as part of the gene therapy treatment protocol.
- the present disclosure provides a system that can be added to a cell collection and/or manufacturing system to enrich and/or transduce a cell population with target cell-specific enriching magnetic beads and vector-magnetic bead complexes during collection of the cell population.
- FIG. 1 Schema of simplified workflow for ex vivo lentiviral vector transduction of human hematopoietic stem and progenitor cells for gene therapy applications.
- A Platelet removal centrifugation from G-CSF mobilized leukapheresis products on the Cytiva Sepax-C ProTM device (Cytiva life sciences, Marlborough, MA, USA).
- B Manual magnetic-bead-based purification and magnetically-assisted lentiviral transduction (MAT) of target cells.
- C Formulation of cell product on Cytiva Sepax-C ProTM device.
- D Evaluation of quality and sterility of cell product.
- FIG. 2 Schematic of standard manufacturing for autologous lentiviral (LV)-transduced gene therapy products.
- FIG. 3 Schematic of simplified manufacturing for autologous LV-transduced gene therapy according to an embodiment.
- Simplified manufacturing for autologous LV-transduced gene therapy products reduces the cost of goods, manufacturing time, and infrastructure requirements and improves patient experience.
- the simplified method includes advancements over current standard manufacturing at steps 4, 6, 8, and 9.
- data shows that the amount of lentivirus required can be reduced to a single administration of 10 infectious particles per cell. This is half to 1/1 Oth the dose currently used in standard processes, thus reducing costs and goods.
- the single-shot administration of lentivirus cuts down on the hands-on time required for manufacturing and eliminates the need to culture cells to facilitate transduction (reducing the cost of goods and hands-on time, as well as the extent of cell manipulation as it pertains to release criteria testing).
- the products considered “minimally manipulated” include the products not cultured and have fewer release criteria requirements for re-administration.
- the ability to manufacture LV-transduced cells ex vivo in less than 1 day allows removing the need for chemotherapy-based conditioning. Certain mobilization agents such as plerixafor and Gro- beta are conducive to opening up the niche, and blood stem cells mobilized with these agents for the original collection process will not have enough time to replace their lost numbers before readministration occurs.
- transduced stem cells will be on equal footing to return to their original niches if reinfused quickly after collection.
- step 9 the patient does not have to receive chemotherapy and supportive care while the blood system is rebuilt. Management and supportive care of chemotherapy-associated effects is not necessary since the blood system was not destroyed by chemotherapy. Instead, only supportive care necessary to control the patient’s disease is needed until the gene therapy is effective.
- FIG. 4 Image of systems in use to leverage magnetically-based purification of blood stem cells.
- the workflow disclosed herein covers implementation with any magnet-enabled cell manufacturing system currently in use clinically or preclinically (or hereafter developed). This will facilitate widespread validation and use of the process both commercially and in development.
- FIG. 5 Universal adaptor device permits purification and transduction in real-time during collection to enable treatment in a single patient visit.
- the simplified manufacturing process can be further streamlined by the purification and magnetically-assisted transduction occurring in a universal adaptor device which can be added to the collection device (apheresis machine).
- This would minimize vein-to-vein time and kits can be provided with the desired therapeutic lentiviral vector.
- This minimizes interventions and time in clinic for the patient, without introducing the safety risks associated with in vivo gene therapy approaches for blood stem cells. Namely, these include ensuring enough blood stem cells receive the gene therapy to be beneficial for the patient’s disease outcome, and also ensuring that other cell types that receive the gene therapy are not harmed or do not result in unwanted off-target side effects.
- FIG. 6 Purity of CD34+ cells isolated from single leukopaks using the simplified workflow facilitated by Sepax-C ProTM is comparable to the state-of- the-art cell isolation protocol on the CliniMACS ProdigyTM (Miltenyi Biotech, Gaithersburg, MD, USA).
- FIG. 7 Transduction efficiency of lentiviral vectors. Higher expression levels of reporter gene, GFP by CD34+ cells (GFP+CD34+) cells when a cocal virus envelope protein pseudotyped lentiviral vector was used compared to a vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped lentiviral vector. Cocal lentivirus vector was produced at titers as high as 10 9 [0016] FIG. 8. Human CD34+ cells transduced using MAT demonstrated the highest efficiency relative to standard transduction conditions with the same vector at a MOI of 10 lentiviral particles/cell (averaged and discrete results shown).
- FIG. 9 Mice transplanted with freshly transduced cells had higher levels of engraftment (hCD45+) without transduction effects compared to mice receiving cultured cells (p ⁇ 0.005).
- FIG. 10 Cultured transplants had higher expression of the GFP reporter gene. Given that fresh transplants had better engraftment (FIG. 9), they had a higher absolute number of cells expressing GFP than cultured cells. Cultured transplants had the advantage of a longer contact time with the virus hence higher efficiency.
- FIG. 11 Mice transplanted with freshly transduced cells had higher levels of engraftment (hCD45+) without transduction effects compared to mice receiving cultured cells (p ⁇ 0.005).
- the present disclosure provides a simplified workflow for ex vivo viral vector transduction of cells.
- the simplified workflow is accomplished by enriching and transducing target cells by performing magnetic-bead-based enrichment and magnetically- assisted viral transduction (MAT), sequentially or simultaneously.
- the method of simplified workflow includes obtaining a cell population including target cells, exposing the cell population to target-cell enriching magnetic beads that alter the location of the target cells within the cell population, contacting the cell population with vector-magnetic bead complexes, and/or applying a magnetic field to the cell population.
- the vector is a lentiviral vector.
- the vector may additionally include an effector molecule that enhances gene delivery and/or facilitates cell or intracellular targeting of gene vectors.
- Such molecules include membranedestabilizing or membrane-permeabilizing molecules such as synthetic peptides, natural or synthetic receptor ligands including antibodies, or signal peptides such as nuclear localization signal peptides.
- the method further includes formulating a cell product for administration to a subject.
- the method further includes evaluating the quality and sterility of the cell product.
- target cells can be simultaneously enriched and transduced. This method of manufacturing cells is beneficial because it does not require culture of cells during transduction and it greatly reduces the vector particle burden per product.
- the present disclosure further describes a method of treating a subject in need of gene therapy.
- the method of treating the subject includes collecting a cell population from the subject wherein the cell population includes target cells, enriching target cells from the rest of the cell population with target-cell enriching magnetic beads, transducing target cells with vector- magnetic bead complexes, applying a magnetic field to the cell population, and formulating and administering transduced target cells to the subject.
- the method of treating further includes, harvesting and washing transduced target cells, performing release testing of transduced target cells, and/or administering a mobilizing agent to the subject.
- the subject does not receive chemotherapy or other cell suppressive treatments between the collecting and the administering.
- the subject does not receive chemotherapy or other cell suppressive treatments as part of the gene therapy treatment protocol. This method of treating a subject is beneficial because it is mobilization- facilitated and does not require chemotherapy during the treatment.
- the present disclosure provides a system that can be added to a cell collection and/or manufacturing system to enrich and/or transduce a cell population with target cell-specific enriching magnetic beads and vector-magnetic bead complexes during collection of the cell population.
- the simplified workflow described herein is beneficial because it maintains the quality and performance of the product with a greatly reduced cost of goods, decreased time, requires less sophisticated infrastructure requirements, and enables the development and evaluation of reduced-intensity patient experiences (e.g., no-chemotherapy conditioning). These improvements to gene therapy cell manufacture and treatment will allow more patients to benefit from gene therapy, make gene therapies more affordable, provide a better patient experience, and reduce interventions and treatment time.
- a patient may be screened to determine if they are a suitable candidate for gene therapy as shown in step 1 of FIG. 3. If the patient is suitable for gene therapy, a cell population including target cells may be collected from a patient or donor.
- target allogenic or autologous cells include hematopoietic stem cells and/or hematopoietic progenitor cells (HSPC).
- HSPC can be chosen for genetic therapies in part due to their ability to self-renew and/or differentiate into (i) myeloid progenitor cells which ultimately give rise to monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets, or dendritic cells; or (ii) lymphoid progenitor cells which ultimately give rise to T-cells, B-cells, and lymphocyte-like cells called natural killer cells (NK-cells).
- myeloid progenitor cells which ultimately give rise to monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets, or dendritic cells
- lymphoid progenitor cells which ultimately give rise to T-cell
- HSPC can be positive for a specific marker expressed in increased levels on HSPC relative to other types of hematopoietic cells.
- markers include CD34, CD43, CD45RO, CD45RA, CD49f, CD59, CD90, CD109, CD117, CD133, CD166, HLA DR, or a combination thereof.
- the HSPC can be negative for an expressed marker relative to other types of hematopoietic cells.
- such markers include Lin, CD38, or a combination thereof.
- the HSPC are CD34+ cells or cell fractions depleted of lineage-specific markers including CD3, CD4, CD8, CD13, CD14, CD15, CD16, CD19, CD20, CD56 or any combination thereof.
- Sources of HSPC include cord blood, peripheral blood, and bone marrow, therefore, these sources are exemplary samples to be obtained at step 2 of FIG. 3.
- Methods regarding the collection, anti-coagulation, and processing, etc. of blood samples are well known in the art. See, for example, Alsever et al., 1941, N.Y. St. J. Med. 41 :126; De Gowin, et al., 1940, J. Am. Med. Ass. 114:850; Smith, et al., 1959, J. Thorac. Cardiovasc. Surg. 38:573; Rous and Turner, 1916, J. Exp. Med. 23:219; and Hum, 1968, Storage of Blood, Academic Press, New York, pp. 26-160.
- HSPC in peripheral blood are preferably mobilized prior to collection.
- Peripheral blood HSPC can be mobilized by any method known in the art.
- Peripheral blood HSPC can be mobilized by treating the subject with any agent(s), described herein or known in the art, that increase the number of HSPC circulating in the peripheral blood of the subject.
- peripheral blood is mobilized by treating the subject with one or more cytokines or growth factors (e.g., G-CSF, kit ligand (KL), IL-I, IL-7, IL-8, IL-11 , Flt3 ligand, SCF, thrombopoietin, or GM-CSF (such as sargramostim)).
- cytokines or growth factors e.g., G-CSF, kit ligand (KL), IL-I, IL-7, IL-8, IL-11 , Flt3 ligand, SCF, thrombopoietin, or GM-
- peripheral blood is mobilized by treating the subject with one or more chemokines (e.g., macrophage inflammatory protein-1a (MIP1a/CCL3)), chemokine receptor ligands (e.g., chemokine receptor 2 ligands GROp and GRO£A4), chemokine receptor analogs (e.g., stromal cell-derived factor-1a (SDF-1a) protein analogs such as CTCE-0021 , CTCE-0214, or SDF-1a such as Met-SDF-ip), or chemokine receptor antagonists (e.g., chemokine (C-X-C motif) receptor 4 (CXCR4) antagonists such as AMD3100).
- chemokines e.g., macrophage inflammatory protein-1a (MIP1a/CCL3)
- chemokine receptor ligands e.g., chemokine receptor 2 ligands GROp and GRO£A4
- chemokine receptor analogs e
- peripheral blood is mobilized by treating the subject with one or more anti-integrin signaling agents (e.g., function blocking anti-very late antigen 4 (VLA-4) antibody, or anti-vascular cell adhesion molecule 1 (VCAM-1)).
- anti-integrin signaling agents e.g., function blocking anti-very late antigen 4 (VLA-4) antibody, or anti-vascular cell adhesion molecule 1 (VCAM-1)
- peripheral blood is mobilized by treating the subject with one or more cytotoxic drugs such as cyclophosphamide, etoposide, or paclitaxel.
- peripheral blood can be mobilized by administering to a subject one or more of the agents listed above for a certain period of time.
- the subject can be treated with one or more agents (e.g., G-CSF) via injection (e.g., subcutaneous, intravenous, or intraperitoneal), once daily or twice daily, for 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days prior to collection of HSPC.
- agents e.g., G-CSF
- injection e.g., subcutaneous, intravenous, or intraperitoneal
- HSPC are collected within 1 , 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, or 24 hours after the last dose of an agent used for mobilization of HSPC into peripheral blood.
- HSPC are mobilized by treating the subject with two or more different types of agents described above or known in the art, such as a growth factor (e.g., G-CSF) and a chemokine receptor antagonist (e.g., CXCR4 receptor antagonist such as AMD3100), or a growth factor (e.g., G-CSF or KL) and an anti-integrin agent (e.g., function blocking VLA-4 antibody).
- a growth factor e.g., G-CSF
- chemokine receptor antagonist e.g., CXCR4 receptor antagonist such as AMD3100
- an anti-integrin agent e.g., function blocking VLA-4 antibody
- different types of mobilizing agents are administered concurrently or sequentially.
- HSPC from peripheral blood can be collected from the blood through a syringe or catheter inserted into a subject's vein.
- the peripheral blood can be collected using an apheresis machine. Blood flows from the vein through the catheter into an apheresis machine, which separates the white blood cells, including HSPC from the rest of the blood and then returns the remainder of the blood to the subject's body. Apheresis can be performed for several days (e.g., 1 to 5 days) until enough HSPC have been collected.
- HSPC from bone marrow can be obtained, e.g., directly from bone marrow from the posterior iliac crest by needle aspiration (see, e.g., Kodo et al., 1984, J. Clin Invest. 73:1377- 1384), or from the blood following pre-treatmentwith cytokines (such as G-CSF and/or AM D3100) that induce cells to be released from the bone marrow compartment.
- cytokines such as G-CSF and/or AM D3100
- platelets can be removed while no further cell enrichment is performed.
- the collected cells can be enriched for cells of interest. While any separation method may be used, in some aspects, immunomagnetic bead-based separation may be used.
- an antibody/bead complex is incubated with a cell population. The antibody/bead complex binds to cells expressing the corresponding epitope. When the cell population is placed into a magnetic field, magnetically labeled cells are retained while unlabeled cells may be removed. This process is referred to as positive selection. Negative selection may also be used.
- a sample is processed to enrich for CD34+ cells using anti- CD34 antibodies directly or indirectly conjugated to magnetic particles in connection with a magnetic cell separator which employs nano-sized super-paramagnetic particles composed of iron oxide and dextran coupled to specific monoclonal antibodies.
- the cell separator can be a closed sterile system, outfitted with single-use disposable tubing.
- Particular embodiments can alternatively include negative selection, selecting for non-CD34 cells, and allowing only CD34+ cells to pass through a selection paradigm.
- antibodies selecting for CD133+ cells, CD43+ cells, CD45RO+ cells, CD45RA+ cells, CD49f+ cells, CD59+ cells, CD90+ cells, CD109+ cells, CD11+ cells 7, CD166+ cells, or a combination of the foregoing can be enriched using antibodies in positive selection embodiments.
- antibodies selecting for CD3+ cells, CD4+ cells, CD8+ cells, CD13+ cells, CD14+ cells, CD15+ cells, CD16+ cells, CD19+ cells, CD20+ cells, CD56+ cells, or a combination of the foregoing can be depleted using antibodies in negative selection embodiments.
- enrichment refers to altering the location of target cells within a cell population relative to other cell types in the cell population.
- enrichment can refer to drawing target cells toward a magnet, relative to other cell types within a cell population (see, for example, FIG. 1 , panel B).
- cells of interest are plated at a desired density.
- the desired density is 2 x 10 6 , though greater and lesser densities may also be used, depending on the cell type.
- plated cells may be exposed to growth conditions.
- Growth conditions include exposure to of growth factors, such as: angiopoietin-like proteins (Angptls, e.g., Angptl2, Angptl3, Angptl7, Angpt15, and Mfap4); erythropoietin; fibroblast growth factor-1 (FGF- 1); Flt-3 ligand (Flt-3L); granulocyte colony stimulating factor (G-CSF); granulocyte-macrophage colony stimulating factor (GM-CSF); insulin growth factor-2 (IFG-2); interleukin-3 (IL-3); interleukin-6 (IL-6); interleukin-7 (IL-7); interleukin-11 (IL-11); stem cell factor (SCF; also known as the c-kit ligand or mast cell growth factor); thrombopoietin (TPO); and analogs thereof (wherein the analogs include any structural variants of the analogs of the analogs
- Growth conditions can also include the use of Notch agonists, aryl hydrocarbon receptor antagonists, pyrimidoindole derivatives (e.g., UM 729 or UM 171), cytokines, chemokines, steroids (e.g., prostaglandin E2), and/or steroid derivatives during ex vivo cell manufacture.
- Notch agonists e.g., aryl hydrocarbon receptor antagonists
- pyrimidoindole derivatives e.g., UM 729 or UM 171
- cytokines e.g., chemokines
- steroids e.g., prostaglandin E2
- steroid derivatives e.g., steroid derivatives during ex vivo cell manufacture.
- Notch agonists include any compound that binds to or otherwise interacts with Notch proteins or other proteins in the Notch pathway such that Notch pathway activity is promoted.
- exemplary Notch agonists are the extracellular binding ligands Delta and Serrate (e.g., Jagged), RBP JMI Suppressor of Hairless, Deltex, Fringe, or fragments thereof which promote Notch pathway activation. Nucleic acid and amino acid sequences of Delta family members and Serrate family members have been isolated from several species and are described in, for example, WO 1993/12141 ; WO 1996/27610; WO 1997/01571 ; and Gray et al., 1999, Am. J. Path. 154:785- 794.
- the Notch agonist is Delta1ext-lgG.
- Particular embodiments can exclude the use of growth conditions.
- cells of interest are with a vector using MAT.
- a "vector” is a nucleic acid molecule that is capable of transporting another nucleic acid.
- Vectors may be, e.g., viruses, phage, a DNA vector, an RNA vector, a viral vector, a bacterial vector, a plasmid vector, a cosmid vector, and an artificial chromosome vector.
- An "expression vector” is any type of vector that is capable of directing the expression of a protein encoded by one or more genes carried by the vector when it is present in the appropriate environment.
- Viral vectors are usually non-replicating or replication-impaired vectors, which means that the viral vectorcannot replicate to any significant extent in normal cells (e.g., normal human cells), as measured by conventional means (e.g. via measuring DNA synthesis and/or viral titer).
- Nonreplicating or replication-impaired vectors may have become so naturally (i.e., they have been isolated as such from nature) or artificially (e.g., by breeding in vitro or by genetic manipulation).
- MVA modified vaccinia Ankara
- viral vectors are incapable of causing a significant infection in a subject, typically in a mammalian subject.
- the viral vectors may be obtained from retroviruses.
- retroviruses are viruses having an RNA genome.
- a retroviral vector contains all of the cis-acting sequences necessary for the packaging and integration of the viral genome, i.e., (a) a long terminal repeat (LTR), or portions thereof, at each end of the vector; (b) primer binding sites for negative and positive strand DNA synthesis; and (c) a packaging signal, necessary for the incorporation of genomic RNA into virions. More detail regarding retroviral vectors can be found in Boesen, et al., 1994, Biotherapy 6:291-302; Clowes, et al., 1994, J. Clin. Invest.
- Gammaretroviruses refers to a genus of the retroviridae family.
- exemplary gammaretroviruses include mouse stem cell virus, murine leukemia virus, feline leukemia virus, feline sarcoma virus, and avian reticuloendotheliosis viruses.
- Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), simian immunodeficiency virus (SIV), human immunodeficiency virus (HIV), and combinations thereof (see, e.g., Buchscher et al., J. Virol. 66:2731-2739, 1992; Johann et al., J. Virol. 66:1635-1640, 1992; Sommerfelt et al., Virol. 176:58- 59, 1990; Wilson et al., J. Virol. 63:2374-2378, 1989; Miller et al., J. Virol. 65:2220-2224, 1991 ; and PCT/US94/05700).
- MiLV murine leukemia virus
- GaLV gibbon ape leukemia virus
- SIV simian immunodeficiency virus
- HAV human immunodeficiency virus
- lentiviral vectors are lentiviral vectors.
- Lentivirus refers to a genus of retroviruses that are capable of infecting dividing and non-dividing cells and typically produce high viral titers. Lentiviral vectors have been employed in gene therapy for a number of diseases. For example, hematopoietic gene therapies using lentiviral vectors or gamma retroviral vectors have been used for x-linked adrenoleukodystrophy and beta thalassemia. See, e.g., Kohn et al., Clin. Immunol. 135:247-54, 2010; Cartier et al., Methods Enzymol.
- HIV human immunodeficiency virus: including HIV type 1 , and HIV type 2
- equine infectious anemia virus feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus (SIV).
- HIV human immunodeficiency virus: including HIV type 1 , and HIV type 2
- equine infectious anemia virus feline immunodeficiency virus (FIV)
- BIV bovine immune deficiency virus
- SIV simian immunodeficiency virus
- retroviral vectors can be used in the practice of the methods of the invention. These include, e.g., vectors based on human foamy virus (HFV) or other viruses in the Spumavirus genera.
- HBV human foamy virus
- FVs Foamy viruses
- retroviruses are the largest retroviruses known today and are widespread among different mammals, including all non-human primate species, however are absent in humans. This complete apathogenicity qualifies FV vectors as ideal gene transfer vehicles for genetic therapies in humans and clearly distinguishes FV vectors as gene delivery system from HIV -derived and also gammaretrovirus-derived vectors.
- FV vectors are suitable for gene therapy applications because they can (1) accommodate large transgenes (> 9kb), (2) transduce slowly dividing cells efficiently, and (3) integrate as a provirus into the genome of target cells, thus enabling stable long term expression of the transgene(s).
- FV vectors do need cell division for the pre- integration complex to enter the nucleus, however, the complex is stable for at least 30 days and still infective.
- the intracellular half-life of the FV pre-integration complex is comparable to the one of lentiviruses and significantly higher than for gammaretroviruses, therefore FV are also - similar to LV vectors - able to transduce rarely dividing cells.
- FV vectors are natural self-inactivating vectors and are characterized by the fact that they seem to have hardly any potential to activate neighboring genes. In addition, FV vectors can enter any cells known (although the receptor is not identified yet) and infectious vector particles can be concentrated 100-fold without loss of infectivity due to a stable envelope protein. FV vectors achieve high transduction efficiency in pluripotent hematopoietic stem cells and have been used in animal models to correct monogenetic diseases such as leukocyte adhesion deficiency (LAD) in dogs and Fanconi anemia in mice. FV vectors are also used in preclinical studies of p-thalassemia.
- LAD leukocyte adhesion deficiency
- viral vectors include those derived from adenoviruses (e.g., adenovirus 5 (Ad5), adenovirus 35 (Ad35), adenovirus 11 (Ad11), adenovirus 26 (Ad26), adenovirus 48 (Ad48) or adenovirus 50 (Ad50)), adeno-associated virus (AAV; see, e.g., U.S. Pat. No. 5,604,090; Kay et al., Nat. Genet.
- adenoviruses e.g., adenovirus 5 (Ad5), adenovirus 35 (Ad35), adenovirus 11 (Ad11), adenovirus 26 (Ad26), adenovirus 48 (Ad48) or adenovirus 50 (Ad50)
- AAV adeno-associated virus
- alphaviruses cytomegaloviruses (CMV), flaviviruses, herpes viruses (e.g., herpes simplex), influenza viruses, papilloma viruses (e.g., human and bovine papilloma virus; see, e.g., U.S. Pat. No. 5,719,054), poxviruses, vaccinia viruses, etc.
- CMV cytomegaloviruses
- flaviviruses e.g., herpes simplex
- influenza viruses e.g., papilloma viruses (e.g., human and bovine papilloma virus; see, e.g., U.S. Pat. No. 5,719,054)
- poxviruses vaccinia viruses, etc.
- Vectors and other methods to deliver nucleic acids can include regulatory sequences to control the expression of the nucleic acid molecules.
- These regulatory sequences can be eukaryotic or prokaryotic in nature.
- the regulatory sequence can be a tissue specific promoter such that the expression of the one or more therapeutic proteins will be substantially greater in the target tissue type compared to other types of tissue.
- the regulatory sequence can result in the constitutive expression of the one or more therapeutic proteins upon entry of the vector into the cell.
- the regulatory sequences can include inducible sequences. Inducible regulatory sequences are well known to those skilled in the art and are those sequences that require the presence of an additional inducing factor to result in expression of the one or more therapeutic proteins.
- Suitable regulatory sequences include binding sites corresponding to tissue-specific transcription factors based on endogenous nuclear proteins, sequences that direct expression in a specific cell type, the lac operator, the tetracycline operator, and the steroid hormone operator. Any inducible regulatory sequence known to those of skill in the art may be used.
- viral vectors are coupled to magnetic particles to form a complex.
- Magnetic particles refer to magnetically responsive solid phases which are particles or aggregates thereof of micro- to nanometer-ranged size which contain one or more metals or oxides or hydroxides thereof, that react to magnetic force upon the influence of a magnetic field, preferably resulting in an attraction towards the source of the magnetic field or in the acceleration of the particle in a preferred direction of space.
- Magnetic can refer to temporarily magnetic materials, such as ferrimagnetic or ferromagnetic materials. The term, however, also encompasses paramagnetic and superparamagnetic materials.
- magnetic nanoparticles include inorganic, polymeric, virus-like particles VLP(s), liposome, and selfassembling protein nanoparticles.
- Magnetic particles are commercially available from a number of sources, including, for example, Dynabeads, MACS microbeads, ViroMag Stem Transduction enhancer, and the like.
- the beads may be biodegradable.
- the beads may be removed during the process. Because association with vectors can be achieved by a variety of processes, no very specific requirements are imposed on particle shape and size.
- the magnetic beads may be between 50nm to 500 micrometers, 100nm to 400 micrometers, 200nm to 200 micrometers, 300nm to 100 micrometers, or any subset thereof.
- Magnetic particles can be made of one or more materials including ferro-, ferri-, or superparamagnetic compounds, such as iron, cobalt, or nickel, magnetic iron oxides or hydroxides such as Fe3O4, gamma-Fe2O3 or double oxides/hydroxides of two- or three-valent iron with two- or three-valent other metal ions or mixtures of the mentioned oxides or hydroxides.
- Magnetic colloidal iron oxide/hydroxide particles are prepared by precipitation from an acidic iron(ll)/iron(lll)-salt solution upon the addition of bases.
- iron oxide/hydroxide particles are derived upon the addition of equivalent amounts of alkali carbonates (sodium hydrogencarbonate, sodium carbonate, and/or ammonium carbonate) to an acidic iron(ll)/iron(lll) salt solution followed by thermal oxidation to magnetic iron hydroxide and further on to iron oxide.
- alkali carbonates sodium hydrogencarbonate, sodium carbonate, and/or ammonium carbonate
- the final particle size can be adjusted by thermal control of reaction velocity and by choosing appropriate concentrations of the reactants.
- small diameter particles of 20 -100 nm are obtained by timely separated formation of iron (II, III)- carbonate at temperatures of 1-50 °C, preferably at 5-10 °C and subsequent heating. Larger particles of 100 - 1000 nm are obtained at reaction temperatures of 60-100 °C implying a faster transformation of iron(ll,lll)-carbonate to iron(ll,lll)-hydroxide.
- Nano-crystalline magnetic particles from double-oxides or hydroxides of two- or three- valent iron with two- or three-valent metal ions other than iron or mixtures of the corresponding oxides or hydroxides can also be prepared according to the above-mentioned procedures by using a salt solution of the two- or three-valent metals.
- Magnetic double oxides or- hydroxides of the three-valent iron are preferentially prepared with two-valent metal ions selected from the first row of transition metals (such as Co(ll), Mn(ll), Cu(ll) or Ni(ll)), whereas magnetic double oxides or-hydroxides of the two-valent iron are preferentially prepared with three-valent metal ions such as Cr(lll), Gd(lll), Dy(lll) or Sm(lll).
- the magnetic particles are iron oxide particles.
- magnetic particles have a size (i.e. a maximal extension) of up to 2000 nm, up to 1500 nm, up to 1000 nm, up to 800 nm, or up to 600 nm.
- Magnetic particles can be coated with positively or negatively charged electrolytes, such as phosphates, citrates or amines; silanes; fatty acids; or polymers, such as polysaccharides, polyamino acids, proteins or synthetic polymers. These coating compounds can have reactive or derivatizable functional groups or these can be introduced by chemical modification after the coating process.
- positively or negatively charged electrolytes such as phosphates, citrates or amines; silanes; fatty acids; or polymers, such as polysaccharides, polyamino acids, proteins or synthetic polymers.
- Functional groups can have cation exchange properties such as found in xanthate-, xanthide, dicarboxyl-, carboxy methyl-, sulfonate-, sulfate-, triacetate-, phosphonate-, phosphate- , citrate-, tartrate-, carboxylate-, or lactate groups of naturally occurring or synthetic polymers.
- these functional groups can be introduced into natural and synthetic polymers prior to coating or after coating of magnetic particles.
- Naturally occurring polymers are polysaccharides such as starch, dextran, glycosaminoglycans, agar, gum-gatti or gum-guar or analogues thereof.
- Suitable derivatives of synthetic polymers can be based on poly(vinyl alcohol) or poly(vinylpyrrolidone) or polyethylene glycole), poly(lactic acid), poly(lactic-co-glycolic acid) or poly(caprolactone). Also, proteins like casein, collagen, gelatin, albumin, or analogous derivatives thereof are useful coating compounds.
- suitable polymers with ion exchange characteristics are polyacrylic acids, poly(styrene sulfonic acid), poly(vinylphosphoric acid) or polymeric arabinic acid, alginate, pectin or polyaspartic or polyglutamic acid.
- Anion-exchange polymers carry endstanding or internal primary-, secondary amino-, imino-, tertiary amino- or quarternary ammonium groups, such as amino-, alkylamine, dietylaminoethyl-, triethylaminoethyl-, trimethylbenzylammonium-groups.
- these polymers can be of natural or synthetic origin and the cationic functional groups can be inherent or can be grafted by synthetic methods prior to or after coating of magnetic particles. Examples include polysaccharides, proteins, or synthetic polymers and derivates thereof such as chitosan, poly(lysine), polyethylene imine), poly(amine), poly(diallyldimethylammonium) or poly(vinylpyridine).
- Functional groups for covalent coupling can be inherent in such polymers or can be introduced by synthetic methods well known to the one skilled in the art of synthetic chemistry. Examples are aldehyde, diazo, carbodiimide, dichlortriazine, alkyl halogenide, imino carbonate, carboxyl, amino, hydroxyl, or thiol groups.
- the magnetic particles are coupled with one or more oligo- or polycations or oligo- or polyanions.
- said oligo- or polycation or oligo- or polyanion is a compound selected from the group consisting of poly(ethylene imine) (PEI), PEI-streptavidin, PEI-biotin, starch-phosphate, polyaspartic acid, polyacrylic acid, polyacrylic-co-maleic acid and arabinic acid.
- PEI poly(ethylene imine)
- PEI-streptavidin PEI-biotin
- starch-phosphate starch-phosphate
- polyaspartic acid polyacrylic acid
- polyacrylic-co-maleic acid polyacrylic-co-maleic acid and arabinic acid
- PEI-ethoxylated a monolayer of PEI coating the magnetic particle being ethoxylated
- PEI-epichlorhydrin PEI modified with epichlorhydrin
- PEI-sodium dodecyl sulfate PEI modified by a covalent coupling of sodium dodecyl sulfate (SDS) by carbodiimide activation (N-Ethyl-N'-(dimethylaminopropyl)-carbodiimide).
- a complex refers to a finite entity including one or more vector(s) and one or more magnetic particle(s), which are suited for being brought in contact with cells in order to transfect them.
- the ratio of vector and magnetic particles in a complex may vary. For example, the ratios may be 1 :50, 1 :100, 1 :250: 1 :500, 1 :750, 1 :1000, and the like. While these ratios may be in different volumes, in some aspects the working solution has a volume of 50pL. In some aspects, the ratio of vector to magnetic particle may vary with cell density, target dose of vector, and/or the titer of the vector.
- the linkage within a complex between a magnetic particle(s) and a vector(s) is by physical linkage, chemical linkage, or by biological interaction.
- Physical linkage, chemical linkage, or biological interaction includes electrostatic interaction, hydrophobic interaction, hydrophilic interaction, receptor-ligand type interaction, such as biotin-streptavidin or antigen-antibody binding, or lectin-type binding, and interaction of natural or synthetic nucleic acids, such as sequence-specific hybridization, triple helix formation, peptidenucleic acid-nucleic acid interaction and the like. Any combination of the above indicated interactions can be used, including particle/precipitate formation induced by such interactions.
- the magnetic particles can be linked to a vector by a covalent linkage.
- exemplary linkages include amide, ester, thioester, ether, thioether, or disulfide bonds.
- the linkage can be direct by reacting functional groups of the surface coating of the magnetic particle with functional groups of the vector or by using a homo- or hetero-bifunctional linker molecule.
- the linker molecule can also contain a spacer arm consisting of an alkyl chain or of linear or branched, natural or synthetic polymers such as peptides, proteins, polyethylene glycols, or carbohydrates (e.g., glycosaminoglycans, chitosans, starch).
- the preparation of the complexes comprising one or more magnetic particles and one or more vectors may be achieved by any of the methods common to the person skilled in the art and available from the literature.
- vector assembly the process of salt-induced aggregation, a phenomenon well-known in colloid science, may be exploited: Colloidal systems with charged surfaces tend to aggregate (flocculate) due to over-compensation of repulsive (electrostatic) forces by attractive forces upon increasing the ionic strength. This process requires mixing components in salt-containing solvent or mixing in salt-free solvents, followed by addition of salt.
- a complex can also be prepared by biologically linking magnetic particles to the vector via biotin-streptavidin interactions.
- magnetic particles coated with PEI-streptavidin may be added to a vector coupled to PEI-biotin.
- magnetic particles can be connected with vectors using antigen-antibody interactions.
- a further process for preparing a complex is to perform a calcium-phosphate coprecipitation of a vector with magnetic particles.
- Transfection refers to a process of introducing one or more foreign nucleic acid molecule(s) into a cell.
- Foreign may refer to (a) nucleic acid molecule(s) which is/are not part of the genome of the cell nor of any other nucleic acid molecule being present in the cell before said transfection such as extrachromosomal DNA, plasmids, cosmids, or artificial chromosomes including viral vectors.
- foreign can refer to nucleic acid molecules that are, at least partially, homologous with respect to the target cell, however, occur in the vector in a different molecular environment than those naturally occurring in the cell.
- homologous nucleic acid molecules include, e.g., overexpression or antisense constructs.
- the terms MAT and magnetofection refer to transfection using complexes of magnetic particle(s) and vector(s) using the application of a magnetic field.
- a suitable magnetic field refers to magnetic fields that, with regard to the shape of the field and its strength, are suited for attracting the above-described complexes against other forces acting on the complexes, such as diffusion or hydrodynamic forces.
- Suitable magnetic fields generally have an intensity of more than 0.5 Tesla or more than 1 Tesla.
- Magnetic fields can be permanent fields or an electromagnetic fields.
- Permanent fields refer to magnetic fields which are generated by a permanent magnet.
- suitable permanent magnets include high energy, permanent magnets, e.g., made of materials containing neodym.
- Such permanent magnets may be constructed as arrays, as yoke and magnetic return path, or in aperture or sandwich configurations.
- the intensity may be controlled with a suitable measuring instrument such as a Hall probe.
- Electromagnetic fields refer to magnetic fields which are generated by electric current. Applicable examples include nuclear magnetic resonance tomographs. Such devices may be used for generating the field and for diagnosing, supervising, and documenting the distribution and local enrichment of the complexes applied.
- Electromagnetic fields can oscillate. Oscillation refers to magnetic fields that periodically change direction. Such an oscillation may induce kinetic energy in the complexes which may be useful in cases where the vectors are released from the complex and the movement promotes its diffusion.
- Magnetic fields may be applied for a variety of lengths of time. For example, magnetic fields may be applied for 1 minute to 1 hour, 5 minutes to 45 minutes, 10 minutes to 40 minutes, 15 minutes to 35 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes or any fraction thereof.
- cells are transduced multiple times with 20-100 transducing units per cell for two to four days.
- the provided method can use less than half of the conventional amount of transducing units.
- the use of MAT allows for decreased amounts of transducing units to be used and decreased time for transfection, allowing decreased costs.
- fewer than 19, fewer than 15, fewer than 10, or fewer than 5, transducing units per cell may be combined with each cell population.
- the cells of interest and the viral vector combination can be placed over a magnet for an amount of time. Such an amount of time may be 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 1 hour, and the like.
- the cells are extracted and enriched in realtime during collection, allowing for fewer patient visits and decreasing delays in treatment.
- cell enrichment and MAT may take place simultaneously.
- the transfected nucleic acid is stably integrated into the genome of a cell.
- the nucleic acid is stably maintained in a cell as a separate, episomal segment.
- the efficiency of integration, the size of the DNA sequence that can be integrated, and the number of copies of a DNA sequence that can be integrated into a genome can be improved by using transposons.
- Transposons or transposable elements include a short nucleic acid sequence with terminal repeat sequences upstream and downstream.
- Active transposons can encode enzymes that facilitate the excision and insertion of nucleic acid into a target DNA sequence.
- transposable elements have been described in the art that facilitate the insertion of nucleic acids into the genome of vertebrates, including humans. Examples include sleeping beauty (e.g., derived from the genome of salmonid fish); piggyback (e.g., derived from lepidopteran cells and/or the Myotis lucifugus); mariner (e.g., derived from Drosophila); frog prince (e.g., derived from Rana pipiens); Tol2 (e.g., derived from medaka fish); TcBuster (e.g., derived from the red flour beetle Tribolium castaneum) and spinON. CRISPR-Cas systems may also be used.
- sleeping beauty e.g., derived from the genome of salmonid fish
- piggyback e.g., derived from lepidopteran cells and/or the Myotis lucifugus
- mariner e.g., derived from Drosophila
- frog prince
- transduced cells can be cultured before final formulation for, for example, 6 hours, 12 hours, 24 hours, 36 hours, 48 hours, 56 hours, 65 hours, 72 hours, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, or 15 days.
- the transduced cells can then be harvested and washed to provide a transduced cell product.
- the transduced cell product may then by formulated for reinfusion.
- Exemplary carriers include saline, buffered saline, physiological saline, water, Hanks' solution, Ringer's solution, Nonnosol-R (Abbott Labs), Plasma-Lyte A® (Baxter Laboratories, Inc., Morton Grove, IL), glycerol, ethanol, and combinations thereof.
- Therapeutically effective amounts of cells within formulations can be greater than 10 2 cells, greater than 10 3 cells, greater than 10 4 cells, greater than 10 5 cells, greater than 10 6 cells, greater than 10 7 cells, greater than 10 8 cells, greater than 10 9 cells, greater than 10 10 cells, or greater than 10 11 .
- cells are generally in a volume of a liter or less, 500 mis or less, 250 mis or less, or 100 mis or less.
- the density of administered cells is typically greater than 10 4 cells/ml, 10 7 cells/ml, or 10 8 cells/ml.
- formulations disclosed herein can be prepared for administration by, for example, injection, infusion, perfusion, or lavage.
- Methods disclosed herein include producing cells for and/or treating subjects (humans, veterinary animals (dogs, cats, reptiles, birds, etc.), livestock (horses, cattle, goats, pigs, chickens, etc.), and research animals (monkeys, rats, mice, fish, etc.) with genetically-modified cells disclosed herein. Treating subjects includes delivering therapeutically effective amounts. Therapeutically effective amounts include those that provide effective amounts, prophylactic treatments, and/or therapeutic treatments.
- an “effective amount” is the number of cells necessary to result in a desired physiological change in a subject. Effective amounts are often administered for research purposes.
- a prophylactic treatment includes a treatment administered to a subject who does not display signs or symptoms of a condition to be treated or displays only early signs or symptoms of the condition to be treated such that treatment is administered for the purpose of diminishing, preventing, or decreasing the risk of developing the condition.
- a prophylactic treatment functions as a preventative treatment against a condition.
- a "therapeutic treatment” includes a treatment administered to a subject who displays symptoms or signs of a condition and is administered to the subject for the purpose of reducing the severity or progression of the condition.
- the actual dose amount administered to a particular subject can be determined by a physician, veterinarian, or researcher taking into account parameters such as physical and physiological factors including target; body weight; type of condition; severity of condition; upcoming relevant events, when known; previous or concurrent therapeutic interventions; idiopathy of the subject; and route of administration, for example.
- parameters such as physical and physiological factors including target; body weight; type of condition; severity of condition; upcoming relevant events, when known; previous or concurrent therapeutic interventions; idiopathy of the subject; and route of administration, for example.
- in vitro and in vivo assays can optionally be employed to help identify optimal dosage ranges.
- Therapeutically effective amounts to administer can include greater than 10 2 cells, greater than 10 3 cells, greater than 10 4 cells, greater than 10 5 cells, greater than 10 6 cells, greater than 10 7 cells, greater than 10 8 cells, greater than 10 9 cells, greater than 10 10 cells, or greater than 10 11 .
- a minimum dose is 1 x 10 6 cells/kg.
- a minimum dose is 2X10 6 cells/kg subject body weight.
- compositions and formulations disclosed herein can be administered by, for example, injection, infusion, perfusion, or lavage and can more particularly include administration through one or more bone marrow, intravenous, intradermal, intraarterial, intranodal, intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intratumoral, intramuscular, intravesicular, and/or subcutaneous infusions and/or bolus injections.
- the reinfusion formula may be administered to the patient prior to the clearance of a mobilization agent.
- the reinfusion formula may be administered to the patient on the same day as the administration of the mobilization agent or on the same day as MAT.
- nucleic acid including a therapeutic gene can be introduced into target cells disclosed herein.
- the term “gene” refers to a nucleic acid sequence (used interchangeably with polynucleotide or nucleotide sequence) that encodes one or more therapeutic proteins as described herein. This definition includes various sequence polymorphisms, mutations, and/or sequence variants wherein such alterations do not substantially affect the function of the encoded one or more therapeutic proteins.
- the term “gene” may include not only coding sequences but also regulatory regions such as promoters, enhancers, and termination regions. The term further can include all introns and other DNA sequences spliced from the mRNA transcript, along with variants resulting from alternative splice sites.
- Gene sequences encoding the molecule can be DNA or RNA that directs the expression of the one or more therapeutic proteins. These nucleic acid sequences may be a DNA strand sequence that is transcribed into RNA or an RNA sequence that is translated into protein. The nucleic acid sequences include both the full-length nucleic acid sequences as well as non-full-length sequences derived from the full-length protein. The sequences can also include degenerate codons of the native sequence or sequences that may be introduced to provide codon preference in a specific cell type.
- a gene sequence encoding one or more therapeutic proteins can be readily prepared by synthetic or recombinant methods from the relevant amino acid sequence.
- the gene sequence encoding any of these sequences can also have one or more restriction enzyme sites at the 5' and/or 3' ends of the coding sequence in order to provide for easy excision and replacement of the gene sequence encoding the sequence with another gene sequence encoding a different sequence.
- the gene sequence encoding the sequences can be codon optimized for expression in mammalian cells.
- a gene can be selected to provide a therapeutically effective response against a condition that, in particular embodiments, is inherited.
- the condition can be Grave’s Disease, rheumatoid arthritis, pernicious anemia, Multiple Sclerosis (MS), inflammatory bowel disease, systemic lupus erythematosus (SLE), adenosine deaminase deficiency (ADA-SCID) or severe combined immunodeficiency disease (SCID), Wiskott-Aldrich syndrome (WAS), chronic granulomatous disease (CGD), Fanconi anemia (FA), Battens disease, adrenoleukodystrophy (ALD) or metachromatic leukodystrophy (MLD), muscular dystrophy, pulmonary aveolar proteinosis (PAP), pyruvate kinase deficiency, Shwachmann-Diamond- Blackfan anemia, dyskeratosis congenita
- the therapeutic gene may be a gene that encodes a protein and/or a gene whose function has been interrupted.
- Exemplary therapeutic gene and gene products include: soluble CD40; CTLA; Fas L; antibodies to CD4, CD5, CD7, CD52, etc.; antibodies to IL1 , IL2, IL6; an antibody to TOR specifically present on autoreactive T cells; IL4; IL10; IL12; IL13; IL1 Ra, SIL1 RI, SIL1 RII; sTNFRI; sTNFRII; antibodies to TNF; P53, PTPN22, and DRB1*1501/DQB1*0602; globin family genes; WAS; phox; FANC family genes; dystrophin; pyruvate kinase; CLN3; ABCD1 ; arylsulfatase A; SFTPB; SFTPC; NLX2.1 ; ABCA3; GATA1 ; ribo
- Therapeutically effective amounts may provide function to immune and other blood cells and/or microglial cells or may alternatively - depending on the treated condition - inhibit lymphocyte activation, induce apoptosis in lymphocytes, eliminate various subsets of lymphocytes, inhibit T cell activation, eliminate or inhibit autoreactive T cells, inhibit Th-2 or Th-1 lymphocyte activity, antagonize IL1 or TNF, reduce inflammation, induce selective tolerance to an inciting agent, reduce or eliminate an immune-mediated condition; and/or reduce or eliminate a symptom of the immune-mediated condition.
- Therapeutic effective amounts may also provide functional DNA repair mechanisms; surfactant protein expression; telomere maintenance; lysosomal function; breakdown of lipids or other proteins such as amyloids; permit ribosomal function; and/or permit development of mature blood cell lineages which would otherwise not develop such as macrophages other white blood cell types.
- a gene can be selected to provide a therapeutically effective response against diseases related to red blood cells and clotting.
- the disease is a hemoglobinopathy like thalassemia, or a sickle cell disease/trait.
- the therapeutic gene may be, for example, a gene that induces or increases production of hemoglobin; induces or increases production of beta-globin, or alpha-globin; or increases the availability of oxygen to cells in the body.
- the therapeutic gene may be, for example, HBB or CYB5R3.
- Exemplary effective treatments may, for example, increase blood cell counts, improve blood cell function, or increase oxygenation of cells in patients.
- the disease is hemophilia.
- the therapeutic gene may be, for example, a gene that increases the production of coagulation/clotting factor VIII or coagulation/clotting factor IX, causes the production of normal versions of coagulation factor VIII or coagulation factor IX, a gene that reduces the production of antibodies to coagulation/clotting factor VI II or coagulation/clotting factor IX, or a gene that causes the proper formation of blood clots.
- Exemplary therapeutic genes include F8 and F9.
- Exemplary effective treatments may, for example, increase or induce the production of coagulation/clotting factors VIII and IX; improve the functioning of coagulation/clotting factors VIII and IX, or reduce clotting time in subjects.
- a gene can be selected to provide a therapeutically effective response against a lysosomal storage disorder.
- the lysosomal storage disorder is mucopolysaccharidosis (MPS), type I; MPS II or Hunter Syndrome; MPS III or Sanfilippo syndrome; MPS IV or Morquio syndrome; MPS V; MPS VI or Maroteaux-Lamy syndrome; MPS VII or sly syndrome; alpha-mannsidosis; beta-mannosidosis; glycogen storage disease type I , also known as GSDI , von Gierke disease, or T ay Sachs; Pompe disease; Gaucher disease; Fabry disease.
- MPS mucopolysaccharidosis
- the therapeutic gene may be, for example, a gene encoding or inducing production of an enzyme, or that otherwise causes the degradation of mucopolysaccharides in lysosomes.
- exemplary therapeutic genes include IDUA or iduronidase, IDS, GNS, HGSNAT, SGSH, NAGLU, GUSB, GALNS, GLB1 , ARSB, and HYAL1.
- Exemplary effective genetic therapies for lysosomal storage disorders may, for example, encode or induce the production of enzymes responsible for the degradation of various substances in lysosomes; reduce, eliminate, prevent, or delay the swelling in various organs, including the head (exp.
- Macrosephaly the liver, spleen, tongue, or vocal cords; reduce fluid in the brain; reduce heart valve abnormalities; prevent or dilate narrowing airways and prevent related upper respiratory conditions like infections and sleep apnea; reduce, eliminate, prevent, or delay the destruction of neurons, and/or the associated symptoms.
- a gene can be selected to provide a therapeutically effective response against a hyperproliferative disease.
- the hyperproliferative disease is cancer.
- the therapeutic gene may be, for example, a tumor suppressor gene, a gene that induces apoptosis, a gene encoding an enzyme, a gene encoding an antibody, or a gene encoding a hormone.
- Exemplary therapeutic genes and gene products include 101 F6, 123F2 (RASSF1), 53BP2, abl, ABLI, ADP, aFGF, APC, ApoAl, ApoAIV, ApoE, ATM, BAI-1 , BDNF, Beta*(BLU), bFGF, BLC1 , BLC6, BRCA1 , BRCA2, CBFA1 , CBL, C-CAM, CFTR, CNTF, COX-1 , CSFIR, CTS-1 , cytosine deaminase, DBCCR-1 , DCC, Dp, DPC-4, E1A, E2F, EBRB2, erb, ERBA, ERBB, ETS1 , ETS2, ETV6, Fab, FCC, FGF, FGR, FHIT, fms, FOX, FUS 1 , FUS1, FYN, G-CSF, GDAIF, Gene 21 (NPRL2), Gene 26 (CACNA2D2), GM
- a gene can be selected to provide a therapeutically effective response against an infectious disease.
- the infectious disease is human immunodeficiency virus (HIV).
- the therapeutic gene may be, for example, a gene rendering immune cells resistant to HIV infection, or which enables immune cells to effectively neutralize the virus via immune reconstruction, polymorphisms of genes encoding proteins expressed by immune cells, genes advantageous for fighting infection that are not expressed in the patient, genes encoding an infectious agent, receptor or coreceptor; a gene encoding ligands for receptors or coreceptors; viral and cellular genes essential for viral replication including; a gene encoding ribozymes, antisense RNA, small interfering RNA (siRNA) or decoy RNA to block the actions of certain transcription factors; a gene encoding dominant negative viral proteins, intracellular antibodies, intrakines, and suicide genes.
- siRNA small interfering RNA
- Exemplary therapeutic genes and gene products include a2 1 ; av[33; av[35; avp63; BOB/GPR15; Bonzo/STRL-33/TYMSTR; CCR2; CCR3; CCR5; CCR8; CD4; CD46; CD55; CXCR4; aminopeptidase-N; HHV-7; ICAM; ICAM-1 ; PRR2/HveB; HveA; a-dystroglycan; LDLR/a2MR/LRP; PVR; PRR1/HveC; and laminin receptor.
- a therapeutically effective amount for the treatment of HIV may increase the immunity of a subject against HIV, ameliorate a symptom associated with AIDS or HIV, or induce an innate or adaptive immune response in a subject against HIV.
- An immune response against HIV may include antibody production and result in the prevention of AIDS and/or ameliorate a symptom of AIDS or HIV infection of the subject, or decrease or eliminate HIV infectivity and/or virulence.
- Bacteria are also encompassed in the term infectious agent.
- Other infectious agents include, for example, parasites such as members of the Plasmodium genus, the agent that causes malaria.
- Exemplary therapeutic genes affecting the infectivity of parasites include erythrocyte skeletal protein 4.1, glycophorin, p55, and the Duffy allele, which encodes a chemokine receptor.
- Therapeutically effective amounts will, for example, reduce or eliminate the infectious disease or agent. They may also reduce or eliminate a symptom of the infectious disease or agent.
- the genetically-modified cell can be any cell type capable of ex vivo enrichment, modification, and formulation as described herein.
- Exemplary cell types include HSPC positive for one or more of CD34, CD43, CD45RO, CD45RA, CD59, CD90, CD109, CD117, CD133, CD166, HLA D or negative for Lin or CD38; T cells (e.g., a
- ISO clean room standard includes classes: ISO 1 , ISO 2, ISO 3, ISO 4, ISO 5, ISO 6, ISO 7, ISO 8, and ISO 9 with ISO 1 being the cleanest end of the scale.
- An ISO class 4 clean room allows up to 10,000 0.1-pm-sized particles per cubic meter and requires an average airflow velocity of 0.254 - 0.457 meters/second (or 50 - 90 ft/min), 300 - 540 air changes per hour, fan/filter unit (FFU) coverage of 50 - 90%, ULPA filters, and a test particle count every 6 months and an airflow and air-pressure differential every 12 months.
- FFU fan/filter unit
- An ISO class 5 clean room allows up to 100,000 0.1 -pm-sized particles per cubic meter of air and requires an average airflow velocity of 0.203 - 0.406 meters/second (or 40 - 80 ft/min), 240 - 480 Air changes per hour, FFU coverage of 35 - 70%, and a test particle count every 6 months, and airflow and air-pressure differential every 12 months.
- An ISO class 6 clean room allows up to 1 ,000,000 0.1-pm-sized particles per cubic meter and requires an average airflow velocity of 0.127 - 0.203 meters/second (or 25 - 40 ft/min), 150 - 240 air changes per hour, FFU coverage of 25 - 40%, and a test particle count, airflow, and air- pressure differential every 12 months.
- An ISO class 7 clean room allows up to 352,000 0.5-pm-sized particles per cubic meter and requires an average airflow velocity of 0.051 - 0.076 meters/second (or 10 - 15 ft/min), 60 - 90 air changes per hour, FFU coverage of 15 - 20%, and a test particle count, airflow, and air- pressure differential every 12 months.
- An ISO class 8 clean room allows up to 3,520,000 0.5-pm sized particles per cubic meter and requires an average airflow velocity of 0.005 - 0.041 meters/second (or 1 - 8 ft/min), 5 - 48 air changes per hour, FFU coverage of 5- 15%, and a test particle count, airflow, and air-pressure differential every 12 months.
- the provided methods allow for the use of an ISO class 7 clean room, decreasing the requirements and expenses for gene therapy production.
- kits including one or more containers including materials necessary or helpful to practice the platforms disclosed herein.
- Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use, or sale for human administration.
- kits described herein further include instructions for using the kit in the technologies disclosed herein.
- the kit may include instructions regarding sample processing; software program use; user interface guidelines; administration of the genetically-modified and formulated cells; appropriate reference levels to interpret results associated when using the kit; proper disposal of the related waste; and the like.
- the instructions can be in the form of printed instructions provided within the kit or the instructions can be printed on a portion of the kit itself. Instructions may be in the form of a sheet, pamphlet, brochure, CD- Rom, or computer-readable device, or can provide directions to instructions at a remote location, such as a website.
- kits include one or more of: one or more sterile tubing sets; saline solution for intravenous infusion (e.g., Plasmalyte A); 25% human serum albumin (HSA); 6% hetastarch in saline (HES); buffer (e.g., PBS/EDTA); biotinylated anti-CD34 antibody (clone 12.8) (also referred to as 12.8 antibody); CD34 microbeads or other direct-conjugate antibody- magnetic bead complex; GAMMAGARD (IVIg) or other blocking agent (e.g., autologous serum); streptavidin-coated microbeads; tunneled cryobag(s); needle-less spike adapter(s); syringe(s) (e.g., 60mL, 30ml_); concentrated lentivirus; medical gloves; gown and/or face mask.
- the kits may exclude transduction media, cytokines, growth factors, and the like as noted above.
- kits exclude cyto- and/or chemokines, and small molecules or additional agents to promote cell survival and gene transfer.
- Particular embodiments exclude StemSpan SFEM or ACF media (both from Stem Cell Technologies) or XVivo media types (Lonza).
- Particular embodiments exclude recombinant human granulocyte colony stimulating factor (G-CSF), stem cell factor (SCF), thrombopoietin (TPO), flightless 3 ligand (flt3 or flt3L), and interleukins such as interleukin 3 (IL3), interleukin 6 (IL6).
- G-CSF human granulocyte colony stimulating factor
- SCF stem cell factor
- TPO thrombopoietin
- TPO thrombopoietin
- flt3 or flt3L flightless 3 ligand
- interleukins such as interleukin 3 (IL3), interleukin 6 (IL6).
- arylhydrocarbon receptor antagonists e g., StemRegeninl (e.g., Phenol, 4-[2-[[2-benzo[b]thien-3-yl- 9-(1-methylethyl)-9H-purin-6-yl]amino]ethyl]); GNF351 (e.g., N-(2-(3H-lndol-3-yl)ethyl)-9- isopropyl-2-(5-methyl-3-pyridyl)-7H-purin-6-amine,N-(2-(1 H-lndol-3-yl)ethyl)-9-isopropyl- 2-(5- methylpyridin-3-yl)-9H-purin-6-amine); CH223191 (e.g., 1-Methyl-/V-[2-methyl-4-[2-(2- methylphenyl)diazenyl]phenyl-1H-pyrazole-5-carboxamide
- a method including: obtaining a cell population including target cells, exposing the cell population to target-cell enriching magnetic beads, contacting the target cells with vector-magnetic bead complexes, and applying a magnetic field to the target cells resulting in transduction of the target cells with the vector.
- stem cells include hematopoietic stem cells.
- target cells include immune cells.
- target-cell enriching magnetic beads include a magnetic bead and a binding domain that binds the target cells.
- vector-magnetic bead complexes include a magnetic bead and a vector.
- a method of providing ex vivo gene therapy to a subject in need thereof including: collecting a cell population from the subject wherein the cell population includes target cells, enriching the target cells in the cell population by exposing the cell population to target-cell enriching magnetic beads, applying a magnetic field to the cell population in the presence of vector-magnetic bead complexes thereby transducing the target cells, and formulating and administering transduced target cells to the subject.
- stem cells include hematopoietic stem cells.
- the target-cell enriching magnetic beads include a magnetic bead and a binding domain that binds the target cells.
- An apparatus including a docking unit, an entry port, and a magnet, wherein the docking unit includes an interface between the apparatus and a cell collection and/or manufacturing system.
- EXAMPLE I Comparison of standard culture based transduction, spinoculation, and MAT of CD34+ cells with cocal and VSV-G lentivirus. Healthy adult, CD34+ cells mobilized with G-CSF were obtained from four unique donors, 2 females and 2 males. The cells were transduced with either cocal virus envelope glycoprotein pseudotyped LV (cocal LC) or vesicular stomatitis virus envelope glycoprotein pseudotyped LV (VSV-G LV) encoding a green fluorescent protein (GFP) transgene using one of three transduction processes (1) standard culture-based transduction, (2) spinoculation, or (3) MAT.
- cocal virus envelope glycoprotein pseudotyped LV cocal LC
- VSV-G LV vesicular stomatitis virus envelope glycoprotein pseudotyped LV
- GFP green fluorescent protein
- the cells were slow-thawed at 37°C for 30 minutes. The cells were then stimulated for 16- 24 hours at 37°C and 5%CO2 in Stem SpanTM SFEM II media containing recombinant human stem cell factor (SCF), thrombopoietin (TPO) and Fms-like tyrosinekinase 3 ligand (FLT3-L) at 100ng/ml each (Stemcell Technologies (Seattle, WA, USA)).
- SCF human stem cell factor
- TPO thrombopoietin
- FLT3-L Fms-like tyrosinekinase 3 ligand
- LV were incubated in ViroMag STEMTM at a dilution of 1:500 for 20 minutes (OZ biosciences, France) then added to CD34+ cells in culture media and placed on a CTSTM DynaMagTM magnet (Thermo Fisher Scientific, Waltham, MA) for 30 minutes.
- the CTSTM DynaMagTM magnet (Thermo Fisher Scientific, Waltham, MA) was set at 0° and the 6-well plate was placed at the center of the magnet.
- Cells were seeded at 2 x 10 6 , transduced once at 10 transducing units (TU) per cell, and cultured post-transduction in Stem SpanTM SFEM II media containing SCF, TPO, and FLT3-L at 100ng/ml each (Stemcell Technologies (Seattle, WA, USA)) for 24 hours. After 24 hours, cells were harvested and washed by centrifuging at 400g for 5 minutes.
- TU transducing units
- Cell pellets were resuspended in Iscove’s Modified Dulbecco’s medium containing 10% v/v heat-inactivated fetal bovine serum and recombinant human stem cell factor (SCF), thrombopoietin (TPO) and Fms-like tyrosinekinase 3 ligand (FLT3-L) at 100ng/ml each (Stemcell Technologies (Seattle, WA, USA)) and cultured for another 9 days at 37°C, 5% CO2.
- SCF fetal bovine serum and recombinant human stem cell factor
- TPO thrombopoietin
- FLT3-L Fms-like tyrosinekinase 3 ligand
- LDLR low-density lipoprotein receptor
- EXAMPLE II In vivo engraftment of MAT-treated cells in NOD/SCID gamma-/- (NSG) immunodeficient juvenile.
- NSG NOD/SCID gamma-/-
- HSPCs, CD34+ Primary human hematopoietic stem and progenitor cells from G-CSF mobilized adult donors were slow-thawed at 37°C for 30 minutes.
- the cells were then stimulated for 16-24 hours at 37°C and 5%CO2 in Stem SpanTM SFEM II media containing recombinant human stem cell factor (SCF), thrombopoietin (TPO) and Fms-like tyrosinekinase 3 ligand (FLT3-L) at 50ng/ml each (Stemcell Technologies (Seattle, WA, USA)).
- SCF human stem cell factor
- TPO thrombopoietin
- FLT3-L Fms-like tyrosinekinase 3 ligand
- the CTSTM DynaMagTM magnet (Thermo Fisher Scientific, Waltham, MA) was set at 0°.
- the pre-stimulated cells were transduced with a single dose of 10 transducing units of cocal virus envelope glycoprotein pseudotyped LV (cocal LV) per cell.
- mice were injected with 1x10 6 human HSPCs either freshly transduced or transduced and then cultured in StemSpanTM containing recombinant human stem cell factor (SCF), thrombopoietin (TPO) and Fms-like tyrosinekinase 3 ligand (FLT3-L) at 50ng/ml each (Stemcell Technologies (Seattle, WA, USA)) for2 days. Animals were monitored for any indication of toxicity and human hematopoiesis was evaluated via peripheral blood draws and flow cytometry bi-weekly for a period of 16 weeks after transplant. A necroscopy of bone marrow, spleen, liver and peripheral was performed.
- SCF recombinant human stem cell factor
- TPO thrombopoietin
- FLT3-L Fms-like tyrosinekinase 3 ligand
- Engraftment of genetically modified blood cells was monitored by flow cytometry using a fluorophore-conjugated anti-human CD45 antibody and GFP detection, and by RT-PCR for integrated lentiviral proviral vector sequences (vector copy number; VCN).
- Vector integration was assessed by sequencing on the Illumina MiSeq platform. Animal health was monitored by visual inspection and weight monitoring under Good Laboratory Practice (GLP) standards.
- GLP Good Laboratory Practice
- mice transplanted with freshly transduced cells had higher levels of engraftment (hCD45+) without transduction effects compared to mice receiving cultured cells (p ⁇ 0.005).
- each embodiment disclosed herein can comprise, consist essentially of, or consist of its particular stated element, step, ingredient, or component.
- the terms “include” or “including” should be interpreted to recite: “comprise, consist of, or consist essentially of.”
- the transition term “comprise” or “comprises” means has, but is not limited to, and allows for the inclusion of unspecified elements, steps, ingredients, or components, even in major amounts.
- the transitional phrase “consisting of” excludes any element, step, ingredient, or component not specified.
- the transition phrase “consisting essentially of’ limits the scope of the embodiment to the specified elements, steps, ingredients, or components and to those that do not materially affect the embodiment.
- the term “about” has the meaning reasonably ascribed to it by a person skilled in the art when used in conjunction with a stated numerical value or range, i.e. denoting somewhat more or somewhat less than the stated value or range, to within a range of ⁇ 20% of the stated value; ⁇ 19% of the stated value; ⁇ 18% of the stated value; ⁇ 17% of the stated value; ⁇ 16% of the stated value; ⁇ 15% of the stated value; ⁇ 14% of the stated value; ⁇ 13% of the stated value; ⁇ 12% of the stated value; ⁇ 11 % of the stated value; ⁇ 10% of the stated value; ⁇ 9% of the stated value; ⁇ 8% of the stated value; ⁇ 7% of the stated value; ⁇ 6% of the stated value; ⁇ 5% of the stated value; ⁇ 4% of the stated value; ⁇ 3% of the stated value; ⁇ 2% of the stated value; or ⁇ 1% of the stated value.
Abstract
Systems and methods to simplify ex vivo gene therapy are described. The systems and methods provide ex vivo manufacturing of cells using target-cell enriching magnetic beads, vector-magnetic bead complexes, and a magnetic field. The present disclosure reduces the amount of required vector to 10 infectious particles per cell and does not require the use of transduction culture or cytokines. Cell manufacturing can be completed within one day, such that treated subjects do not require chemotherapy between cell collection and re-administration.
Description
SYSTEMS AND METHODS FOR GENE THERAPY
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application No. 63/379,885 filed October 17, 2022, and entitled “Systems and Methods for Gene Therapy.” The referenced application is incorporated herein in its entirety.
FIELD OF THE DISCLOSURE
[0002] The current disclosure describes systems and methods to simplify gene therapy. The present disclosure provides a method of manufacturing cells ex vivo using magnetic field transfection. The present disclosure also provides a method of treating a subject in need thereof with the manufactured cells and a system that can be added to a cell collection and/or manufacturing system to perform the methods disclosed herein.
BACKGROUND OF THE DISCLOSURE
[0003] Lentiviral vector gene therapy delivered to blood cells such as stem cells has dramatically improved the outcome and quality of life for persons diagnosed with genetic, malignant, and infectious diseases that affect tens of millions of patients worldwide. Current state of the art methods of ex vivo gene therapy require the collection of a stem cell mobilized apheresis product from a patient, followed by initial platelet and plasma washing, then purification of rare blood stem cells (CD34+) via immunomagnetic beads and a magnetic field in which bead-bound cells are retained. Once desired CD34+ cells are purified, they are stimulated in culture conditions which require specialized media and supplements. Then lentivirus vector supernatants are added for transduction over days. Finally, transduced cells are washed to remove any unused virus, and formulated for release testing, storage, and infusion into the patient. This process requires 3-4 days of manufacturing time in an International Standards Organization (ISO) class 5 clean room to maintain product sterility and quality.
[0004] Despite its success, gene therapy is still limited in its potential to treat the large numbers of patients in need owing to the scale and complexity of manufacturing autologous, genetically modified stem cells, as well as the limited availability of reagents and the cost of goods. With prices for current U.S. Food and Drug Administration (FDA) approved gene therapy products exceeding $373,000 (USD), gene therapy is not affordable for patients in low-and middle-income countries (LMIC) and is not sustainable for healthcare economies of high-income countries. A lower cost gene therapy product with equivalent or better safety and efficacy would be a major advance with the potential for any disease indication treated with lentivirus vector transduced
autologous blood stem cells.
SUMMARY OF THE DISCLOSURE
[0005] Current production platforms are time consuming and expensive. The present disclosure provides a method of simplified workflow for ex vivo lentiviral vector transduction of cells. In particular embodiments, the simplified workflow is accomplished by enriching and transducing target cells by performing magnetic-bead-based enrichment and magnetically-assisted viral transduction (MAT), sequentially or simultaneously. In particular embodiments, the simplified workflow includes obtaining a cell population including target cells, exposing the cell population to target-cell enriching magnetic beads, contacting the cell population with vector-magnetic bead complexes, and/or applying a magnetic field to the cell population during transduction. The exposing, contacting, and applying may be applied simultaneously or sequentially. In some aspects, the cell population is exposed to target-cell-enriching magnetic beads prior to contacting the cell population with vector-magnetic bead complexes and/or applying a magnetic field to the cell population during transduction. In particular embodiments, the vector is a lentiviral vector. In particular embodiments, the method further includes formulating a cell product for administration to a subject. In particular embodiments, the method further includes evaluating the quality and sterility of the cell product. In particular embodiments of the disclosed methods, target cells can be simultaneously enriched and transduced.
[0006] The present disclosure further describes a method of treating a subject in need of gene therapy. The method of treating the subject includes collecting a cell population from the subject wherein the cell population includes target cells, enriching stem cells from the rest of the cell population with target-cell enriching magnetic beads, transducing target cells with vector- magnetic bead complexes, applying a magnetic field to the cell population, and formulating and administering transduced target cells to the subject. In particular embodiments, the method of treating further includes, harvesting and washing transduced target cells, performing release testing of transduced target cells, and/or administering a mobilizing agent to the subject prior to collection of the cell population. In particular embodiments, the subject does not receive chemotherapy or other cell suppressive treatments between the collecting and the administering. In particular embodiments, the subject does not receive chemotherapy or other cell suppressive treatments as part of the gene therapy treatment protocol.
[0007] Furthermore, the present disclosure provides a system that can be added to a cell collection and/or manufacturing system to enrich and/or transduce a cell population with target cell-specific enriching magnetic beads and vector-magnetic bead complexes during collection of
the cell population.
BRIEF DESCRIPTION OF THE FIGURES
[0008] Some of the drawings submitted herewith may be better understood in color. Applicant considers the color versions of the drawings as part of the original submission and reserves the right to present color images of the drawings in later proceedings.
[0009] FIG. 1. Schema of simplified workflow for ex vivo lentiviral vector transduction of human hematopoietic stem and progenitor cells for gene therapy applications. (A) Platelet removal centrifugation from G-CSF mobilized leukapheresis products on the Cytiva Sepax-C Pro™ device (Cytiva life sciences, Marlborough, MA, USA). (B) Manual magnetic-bead-based purification and magnetically-assisted lentiviral transduction (MAT) of target cells. (C) Formulation of cell product on Cytiva Sepax-C Pro™ device. (D) Evaluation of quality and sterility of cell product.
[00010] FIG. 2. Schematic of standard manufacturing for autologous lentiviral (LV)-transduced gene therapy products.
[0011] FIG. 3. Schematic of simplified manufacturing for autologous LV-transduced gene therapy according to an embodiment. Simplified manufacturing for autologous LV-transduced gene therapy products reduces the cost of goods, manufacturing time, and infrastructure requirements and improves patient experience. The simplified method includes advancements over current standard manufacturing at steps 4, 6, 8, and 9. At step 4, data shows that the amount of lentivirus required can be reduced to a single administration of 10 infectious particles per cell. This is half to 1/1 Oth the dose currently used in standard processes, thus reducing costs and goods. Furthermore, the single-shot administration of lentivirus cuts down on the hands-on time required for manufacturing and eliminates the need to culture cells to facilitate transduction (reducing the cost of goods and hands-on time, as well as the extent of cell manipulation as it pertains to release criteria testing). In step 6, the products considered “minimally manipulated” include the products not cultured and have fewer release criteria requirements for re-administration. In step 8, the ability to manufacture LV-transduced cells ex vivo in less than 1 day allows removing the need for chemotherapy-based conditioning. Certain mobilization agents such as plerixafor and Gro- beta are conducive to opening up the niche, and blood stem cells mobilized with these agents for the original collection process will not have enough time to replace their lost numbers before readministration occurs. Thus, transduced stem cells will be on equal footing to return to their original niches if reinfused quickly after collection. In step 9, the patient does not have to receive chemotherapy and supportive care while the blood system is rebuilt. Management and supportive care of chemotherapy-associated effects is not necessary since the blood system was not
destroyed by chemotherapy. Instead, only supportive care necessary to control the patient’s disease is needed until the gene therapy is effective.
[0012] FIG. 4. Image of systems in use to leverage magnetically-based purification of blood stem cells. The workflow disclosed herein covers implementation with any magnet-enabled cell manufacturing system currently in use clinically or preclinically (or hereafter developed). This will facilitate widespread validation and use of the process both commercially and in development.
[0013] FIG. 5. Universal adaptor device permits purification and transduction in real-time during collection to enable treatment in a single patient visit. The simplified manufacturing process can be further streamlined by the purification and magnetically-assisted transduction occurring in a universal adaptor device which can be added to the collection device (apheresis machine). This would minimize vein-to-vein time and kits can be provided with the desired therapeutic lentiviral vector. This minimizes interventions and time in clinic for the patient, without introducing the safety risks associated with in vivo gene therapy approaches for blood stem cells. Namely, these include ensuring enough blood stem cells receive the gene therapy to be beneficial for the patient’s disease outcome, and also ensuring that other cell types that receive the gene therapy are not harmed or do not result in unwanted off-target side effects.
[0014] FIG. 6. Purity of CD34+ cells isolated from single leukopaks using the simplified workflow facilitated by Sepax-C Pro™ is comparable to the state-of- the-art cell isolation protocol on the CliniMACS Prodigy™ (Miltenyi Biotech, Gaithersburg, MD, USA).
[0015] FIG. 7. Transduction efficiency of lentiviral vectors. Higher expression levels of reporter gene, GFP by CD34+ cells (GFP+CD34+) cells when a cocal virus envelope protein pseudotyped lentiviral vector was used compared to a vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped lentiviral vector. Cocal lentivirus vector was produced at titers as high as 109 [0016] FIG. 8. Human CD34+ cells transduced using MAT demonstrated the highest efficiency relative to standard transduction conditions with the same vector at a MOI of 10 lentiviral particles/cell (averaged and discrete results shown).
[0017] FIG. 9. Mice transplanted with freshly transduced cells had higher levels of engraftment (hCD45+) without transduction effects compared to mice receiving cultured cells (p<0.005).
[0018] FIG. 10. Cultured transplants had higher expression of the GFP reporter gene. Given that fresh transplants had better engraftment (FIG. 9), they had a higher absolute number of cells expressing GFP than cultured cells. Cultured transplants had the advantage of a longer contact time with the virus hence higher efficiency.
[0019] FIG. 11. Mice transplanted with freshly transduced cells had higher levels of engraftment (hCD45+) without transduction effects compared to mice receiving cultured cells (p<0.005).
DETAILED DESCRIPTION
[0020] The present disclosure provides a simplified workflow for ex vivo viral vector transduction of cells. In particular embodiments, the simplified workflow is accomplished by enriching and transducing target cells by performing magnetic-bead-based enrichment and magnetically- assisted viral transduction (MAT), sequentially or simultaneously. In particular embodiments, the method of simplified workflow includes obtaining a cell population including target cells, exposing the cell population to target-cell enriching magnetic beads that alter the location of the target cells within the cell population, contacting the cell population with vector-magnetic bead complexes, and/or applying a magnetic field to the cell population. In particular embodiments, the vector is a lentiviral vector.
[0021] The vector may additionally include an effector molecule that enhances gene delivery and/or facilitates cell or intracellular targeting of gene vectors. Such molecules include membranedestabilizing or membrane-permeabilizing molecules such as synthetic peptides, natural or synthetic receptor ligands including antibodies, or signal peptides such as nuclear localization signal peptides. In particular embodiments, the method further includes formulating a cell product for administration to a subject. In particular embodiments, the method further includes evaluating the quality and sterility of the cell product. In particular embodiments of the disclosed methods, target cells can be simultaneously enriched and transduced. This method of manufacturing cells is beneficial because it does not require culture of cells during transduction and it greatly reduces the vector particle burden per product.
[0022] The present disclosure further describes a method of treating a subject in need of gene therapy. The method of treating the subject includes collecting a cell population from the subject wherein the cell population includes target cells, enriching target cells from the rest of the cell population with target-cell enriching magnetic beads, transducing target cells with vector- magnetic bead complexes, applying a magnetic field to the cell population, and formulating and administering transduced target cells to the subject. In particular embodiments, the method of treating further includes, harvesting and washing transduced target cells, performing release testing of transduced target cells, and/or administering a mobilizing agent to the subject. In particular embodiments, the subject does not receive chemotherapy or other cell suppressive treatments between the collecting and the administering. In particular embodiments, the subject does not receive chemotherapy or other cell suppressive treatments as part of the gene therapy treatment protocol. This method of treating a subject is beneficial because it is mobilization- facilitated and does not require chemotherapy during the treatment.
[0023] Furthermore, the present disclosure provides a system that can be added to a cell
collection and/or manufacturing system to enrich and/or transduce a cell population with target cell-specific enriching magnetic beads and vector-magnetic bead complexes during collection of the cell population.
[0024] The simplified workflow described herein is beneficial because it maintains the quality and performance of the product with a greatly reduced cost of goods, decreased time, requires less sophisticated infrastructure requirements, and enables the development and evaluation of reduced-intensity patient experiences (e.g., no-chemotherapy conditioning). These improvements to gene therapy cell manufacture and treatment will allow more patients to benefit from gene therapy, make gene therapies more affordable, provide a better patient experience, and reduce interventions and treatment time.
[0025] A patient may be screened to determine if they are a suitable candidate for gene therapy as shown in step 1 of FIG. 3. If the patient is suitable for gene therapy, a cell population including target cells may be collected from a patient or donor.
[0026] In particular, embodiments, target allogenic or autologous cells include hematopoietic stem cells and/or hematopoietic progenitor cells (HSPC). HSPC can be chosen for genetic therapies in part due to their ability to self-renew and/or differentiate into (i) myeloid progenitor cells which ultimately give rise to monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets, or dendritic cells; or (ii) lymphoid progenitor cells which ultimately give rise to T-cells, B-cells, and lymphocyte-like cells called natural killer cells (NK-cells). For a general discussion of hematopoiesis and HSPC differentiation, see Chapter 17, Differentiated Cells and the Maintenance of Tissues, Alberts et al., 1989, Molecular Biology of the Cell, 2nd Ed., Garland Publishing, New York, NY; Chapter 2 of Regenerative Medicine, Department of Health and Human Services, August 5, 2006, and Chapter 5 of Hematopoietic Stem Cells, 2009, Stem Cell Information, Department of Health and Human Services.
[0027] HSPC can be positive for a specific marker expressed in increased levels on HSPC relative to other types of hematopoietic cells. For example, such markers include CD34, CD43, CD45RO, CD45RA, CD49f, CD59, CD90, CD109, CD117, CD133, CD166, HLA DR, or a combination thereof. Also, the HSPC can be negative for an expressed marker relative to other types of hematopoietic cells. For example, such markers include Lin, CD38, or a combination thereof. Preferably, the HSPC are CD34+ cells or cell fractions depleted of lineage-specific markers including CD3, CD4, CD8, CD13, CD14, CD15, CD16, CD19, CD20, CD56 or any combination thereof.
[0028] Sources of HSPC include cord blood, peripheral blood, and bone marrow, therefore, these sources are exemplary samples to be obtained at step 2 of FIG. 3. Methods regarding the
collection, anti-coagulation, and processing, etc. of blood samples are well known in the art. See, for example, Alsever et al., 1941, N.Y. St. J. Med. 41 :126; De Gowin, et al., 1940, J. Am. Med. Ass. 114:850; Smith, et al., 1959, J. Thorac. Cardiovasc. Surg. 38:573; Rous and Turner, 1916, J. Exp. Med. 23:219; and Hum, 1968, Storage of Blood, Academic Press, New York, pp. 26-160. [0029] HSPC in peripheral blood are preferably mobilized prior to collection. Peripheral blood HSPC can be mobilized by any method known in the art. Peripheral blood HSPC can be mobilized by treating the subject with any agent(s), described herein or known in the art, that increase the number of HSPC circulating in the peripheral blood of the subject. For example, in particular embodiments, peripheral blood is mobilized by treating the subject with one or more cytokines or growth factors (e.g., G-CSF, kit ligand (KL), IL-I, IL-7, IL-8, IL-11 , Flt3 ligand, SCF, thrombopoietin, or GM-CSF (such as sargramostim)). Different types of G-CSF that can be used in the methods for mobilization of peripheral blood include filgrastim and longer acting G-CSF-pegfilgrastim. In particular embodiments, peripheral blood is mobilized by treating the subject with one or more chemokines (e.g., macrophage inflammatory protein-1a (MIP1a/CCL3)), chemokine receptor ligands (e.g., chemokine receptor 2 ligands GROp and GRO£A4), chemokine receptor analogs (e.g., stromal cell-derived factor-1a (SDF-1a) protein analogs such as CTCE-0021 , CTCE-0214, or SDF-1a such as Met-SDF-ip), or chemokine receptor antagonists (e.g., chemokine (C-X-C motif) receptor 4 (CXCR4) antagonists such as AMD3100). In particular embodiments, peripheral blood is mobilized by treating the subject with one or more anti-integrin signaling agents (e.g., function blocking anti-very late antigen 4 (VLA-4) antibody, or anti-vascular cell adhesion molecule 1 (VCAM-1)). In particular embodiments, peripheral blood is mobilized by treating the subject with one or more cytotoxic drugs such as cyclophosphamide, etoposide, or paclitaxel. In particular embodiments, peripheral blood can be mobilized by administering to a subject one or more of the agents listed above for a certain period of time. For example, the subject can be treated with one or more agents (e.g., G-CSF) via injection (e.g., subcutaneous, intravenous, or intraperitoneal), once daily or twice daily, for 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days prior to collection of HSPC. In specific embodiments, HSPC are collected within 1 , 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, or 24 hours after the last dose of an agent used for mobilization of HSPC into peripheral blood. In particular embodiments, HSPC are mobilized by treating the subject with two or more different types of agents described above or known in the art, such as a growth factor (e.g., G-CSF) and a chemokine receptor antagonist (e.g., CXCR4 receptor antagonist such as AMD3100), or a growth factor (e.g., G-CSF or KL) and an anti-integrin agent (e.g., function blocking VLA-4 antibody). In particular embodiments, different types of mobilizing agents are administered concurrently or sequentially. For additional information regarding methods of
mobilization of peripheral blood see, e.g., Craddock et al., 1997, Blood 90(12):4779-4788; Jin et al., 2008, Journal of Translational Medicine 6:39; Pelus, 2008, Cure Opin. Hematol. 15(4):285- 292; Papayannopoulou et al., 1998, Blood 91(7):2231-2239; Tricot et al., 2008, Haematologica 93(11):1739-1742; and Weaver et al., 2001 , Bone Marrow Transplantation 27(2):S23-S29).
[0030] HSPC from peripheral blood can be collected from the blood through a syringe or catheter inserted into a subject's vein. For example, the peripheral blood can be collected using an apheresis machine. Blood flows from the vein through the catheter into an apheresis machine, which separates the white blood cells, including HSPC from the rest of the blood and then returns the remainder of the blood to the subject's body. Apheresis can be performed for several days (e.g., 1 to 5 days) until enough HSPC have been collected.
[0031] HSPC from bone marrow can be obtained, e.g., directly from bone marrow from the posterior iliac crest by needle aspiration (see, e.g., Kodo et al., 1984, J. Clin Invest. 73:1377- 1384), or from the blood following pre-treatmentwith cytokines (such as G-CSF and/or AM D3100) that induce cells to be released from the bone marrow compartment.
[0032] In particular embodiments, platelets can be removed while no further cell enrichment is performed. In particular embodiments, the collected cells can be enriched for cells of interest. While any separation method may be used, in some aspects, immunomagnetic bead-based separation may be used. In particular embodiments, during immunomagnetic bead-based separation, an antibody/bead complex is incubated with a cell population. The antibody/bead complex binds to cells expressing the corresponding epitope. When the cell population is placed into a magnetic field, magnetically labeled cells are retained while unlabeled cells may be removed. This process is referred to as positive selection. Negative selection may also be used. [0033] In particular embodiments, a sample is processed to enrich for CD34+ cells using anti- CD34 antibodies directly or indirectly conjugated to magnetic particles in connection with a magnetic cell separator which employs nano-sized super-paramagnetic particles composed of iron oxide and dextran coupled to specific monoclonal antibodies. The cell separator can be a closed sterile system, outfitted with single-use disposable tubing. Particular embodiments can alternatively include negative selection, selecting for non-CD34 cells, and allowing only CD34+ cells to pass through a selection paradigm. For example, antibodies selecting for CD133+ cells, CD43+ cells, CD45RO+ cells, CD45RA+ cells, CD49f+ cells, CD59+ cells, CD90+ cells, CD109+ cells, CD11+ cells 7, CD166+ cells, or a combination of the foregoing, can be enriched using antibodies in positive selection embodiments. In another example, antibodies selecting for CD3+ cells, CD4+ cells, CD8+ cells, CD13+ cells, CD14+ cells, CD15+ cells, CD16+ cells, CD19+ cells, CD20+ cells, CD56+ cells, or a combination of the foregoing, can be depleted using antibodies in
negative selection embodiments.
[0034] In particular embodiments, enrichment refers to altering the location of target cells within a cell population relative to other cell types in the cell population. For example, enrichment can refer to drawing target cells toward a magnet, relative to other cell types within a cell population (see, for example, FIG. 1 , panel B).
[0035] In particular embodiments, cells of interest are plated at a desired density. In some aspects, the desired density is 2 x 106, though greater and lesser densities may also be used, depending on the cell type.
[0036] In particular embodiments, plated cells may be exposed to growth conditions. Growth conditions include exposure to of growth factors, such as: angiopoietin-like proteins (Angptls, e.g., Angptl2, Angptl3, Angptl7, Angpt15, and Mfap4); erythropoietin; fibroblast growth factor-1 (FGF- 1); Flt-3 ligand (Flt-3L); granulocyte colony stimulating factor (G-CSF); granulocyte-macrophage colony stimulating factor (GM-CSF); insulin growth factor-2 (IFG-2); interleukin-3 (IL-3); interleukin-6 (IL-6); interleukin-7 (IL-7); interleukin-11 (IL-11); stem cell factor (SCF; also known as the c-kit ligand or mast cell growth factor); thrombopoietin (TPO); and analogs thereof (wherein the analogs include any structural variants of the growth factors having the biological activity of the naturally occurring growth factor; see, e.g., WO 2007/1145227 and U.S. Patent Publication No. 2010/0183564).
[0037] Growth conditions can also include the use of Notch agonists, aryl hydrocarbon receptor antagonists, pyrimidoindole derivatives (e.g., UM 729 or UM 171), cytokines, chemokines, steroids (e.g., prostaglandin E2), and/or steroid derivatives during ex vivo cell manufacture.
[0038] Notch agonists include any compound that binds to or otherwise interacts with Notch proteins or other proteins in the Notch pathway such that Notch pathway activity is promoted. Exemplary Notch agonists are the extracellular binding ligands Delta and Serrate (e.g., Jagged), RBP JMI Suppressor of Hairless, Deltex, Fringe, or fragments thereof which promote Notch pathway activation. Nucleic acid and amino acid sequences of Delta family members and Serrate family members have been isolated from several species and are described in, for example, WO 1993/12141 ; WO 1996/27610; WO 1997/01571 ; and Gray et al., 1999, Am. J. Path. 154:785- 794. In particular embodiments, the Notch agonist is Delta1ext-lgG.
[0039] Particular embodiments can exclude the use of growth conditions.
[0040] In particular embodiments, cells of interest are with a vector using MAT. A "vector" is a nucleic acid molecule that is capable of transporting another nucleic acid. Vectors may be, e.g., viruses, phage, a DNA vector, an RNA vector, a viral vector, a bacterial vector, a plasmid vector, a cosmid vector, and an artificial chromosome vector. An "expression vector" is any type of vector
that is capable of directing the expression of a protein encoded by one or more genes carried by the vector when it is present in the appropriate environment.
[0041] Viral vectors are usually non-replicating or replication-impaired vectors, which means that the viral vectorcannot replicate to any significant extent in normal cells (e.g., normal human cells), as measured by conventional means (e.g. via measuring DNA synthesis and/or viral titer). Nonreplicating or replication-impaired vectors may have become so naturally (i.e., they have been isolated as such from nature) or artificially (e.g., by breeding in vitro or by genetic manipulation). There will generally be at least one cell-type in which the replication-impaired viral vector can be grown-for example, modified vaccinia Ankara (MVA) can be grown in CEF cells. Typically, viral vectors are incapable of causing a significant infection in a subject, typically in a mammalian subject.
[0042] In some aspects, the viral vectors may be obtained from retroviruses. "Retroviruses" are viruses having an RNA genome. In particular embodiments, a retroviral vector contains all of the cis-acting sequences necessary for the packaging and integration of the viral genome, i.e., (a) a long terminal repeat (LTR), or portions thereof, at each end of the vector; (b) primer binding sites for negative and positive strand DNA synthesis; and (c) a packaging signal, necessary for the incorporation of genomic RNA into virions. More detail regarding retroviral vectors can be found in Boesen, et al., 1994, Biotherapy 6:291-302; Clowes, et al., 1994, J. Clin. Invest. 93:644-651 ; Kiem, et al., 1994, Blood 83:1467-1473; Salmons and Gunzberg, 1993, Human Gene Therapy 4:129-141 ; Miller, et al., 1993, Meth. Enzymol. 217:581-599; and Grossman and Wilson, 1993, Curr. Opin. in Genetics and Devel. 3:110-114.
[0043] "Gammaretroviruses" refers to a genus of the retroviridae family. Exemplary gammaretroviruses include mouse stem cell virus, murine leukemia virus, feline leukemia virus, feline sarcoma virus, and avian reticuloendotheliosis viruses.
[0044] Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), simian immunodeficiency virus (SIV), human immunodeficiency virus (HIV), and combinations thereof (see, e.g., Buchscher et al., J. Virol. 66:2731-2739, 1992; Johann et al., J. Virol. 66:1635-1640, 1992; Sommerfelt et al., Virol. 176:58- 59, 1990; Wilson et al., J. Virol. 63:2374-2378, 1989; Miller et al., J. Virol. 65:2220-2224, 1991 ; and PCT/US94/05700).
[0045] Particularly suitable vectors are lentiviral vectors. "Lentivirus" refers to a genus of retroviruses that are capable of infecting dividing and non-dividing cells and typically produce high viral titers. Lentiviral vectors have been employed in gene therapy for a number of diseases. For example, hematopoietic gene therapies using lentiviral vectors or gamma retroviral vectors have
been used for x-linked adrenoleukodystrophy and beta thalassemia. See, e.g., Kohn et al., Clin. Immunol. 135:247-54, 2010; Cartier et al., Methods Enzymol. 507:187-198, 2012; and Cavazzana-Calvo et al., Nature 467:318-322, 2010. Several examples of lentiviruses include HIV (human immunodeficiency virus: including HIV type 1 , and HIV type 2); equine infectious anemia virus; feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus (SIV).
[0046] In particular embodiments, other retroviral vectors can be used in the practice of the methods of the invention. These include, e.g., vectors based on human foamy virus (HFV) or other viruses in the Spumavirus genera.
[0047] Foamy viruses (FVs) are the largest retroviruses known today and are widespread among different mammals, including all non-human primate species, however are absent in humans. This complete apathogenicity qualifies FV vectors as ideal gene transfer vehicles for genetic therapies in humans and clearly distinguishes FV vectors as gene delivery system from HIV -derived and also gammaretrovirus-derived vectors.
[0048] FV vectors are suitable for gene therapy applications because they can (1) accommodate large transgenes (> 9kb), (2) transduce slowly dividing cells efficiently, and (3) integrate as a provirus into the genome of target cells, thus enabling stable long term expression of the transgene(s). FV vectors do need cell division for the pre- integration complex to enter the nucleus, however, the complex is stable for at least 30 days and still infective. The intracellular half-life of the FV pre-integration complex is comparable to the one of lentiviruses and significantly higher than for gammaretroviruses, therefore FV are also - similar to LV vectors - able to transduce rarely dividing cells. FV vectors are natural self-inactivating vectors and are characterized by the fact that they seem to have hardly any potential to activate neighboring genes. In addition, FV vectors can enter any cells known (although the receptor is not identified yet) and infectious vector particles can be concentrated 100-fold without loss of infectivity due to a stable envelope protein. FV vectors achieve high transduction efficiency in pluripotent hematopoietic stem cells and have been used in animal models to correct monogenetic diseases such as leukocyte adhesion deficiency (LAD) in dogs and Fanconi anemia in mice. FV vectors are also used in preclinical studies of p-thalassemia.
[0049] Additional examples of viral vectors include those derived from adenoviruses (e.g., adenovirus 5 (Ad5), adenovirus 35 (Ad35), adenovirus 11 (Ad11), adenovirus 26 (Ad26), adenovirus 48 (Ad48) or adenovirus 50 (Ad50)), adeno-associated virus (AAV; see, e.g., U.S. Pat. No. 5,604,090; Kay et al., Nat. Genet. 24:257 (2000); Nakai et al., Blood 91 :4600 (1998)), alphaviruses, cytomegaloviruses (CMV), flaviviruses, herpes viruses (e.g., herpes simplex),
influenza viruses, papilloma viruses (e.g., human and bovine papilloma virus; see, e.g., U.S. Pat. No. 5,719,054), poxviruses, vaccinia viruses, etc. See Kozarsky and Wilson, 1993, Current Opinion in Genetics and Development 3:499-503, Rosenfeld, et al., 1991 , Science 252:431-434; Rosenfeld, et al., 1992, Cell 68:143-155; Mastrangeli, et al., 1993, J. Clin. Invest. 91 :225-234; Walsh, et al., 1993, Proc. Soc. Exp. Bioi. Med. 204:289-300; and Lundstrom, 1999, J. Recept. Signal Transduct. Res. 19: 673-686. Examples include modified vaccinia Ankara (MVA) and NYVAC, or strains derived therefrom. Other examples include avipox vectors, such as a fowlpox vectors (e.g., FP9) or canarypox vectors (e.g., ALVAC and strains derived therefrom).
[0050] Vectors and other methods to deliver nucleic acids can include regulatory sequences to control the expression of the nucleic acid molecules. These regulatory sequences can be eukaryotic or prokaryotic in nature. In particular embodiments, the regulatory sequence can be a tissue specific promoter such that the expression of the one or more therapeutic proteins will be substantially greater in the target tissue type compared to other types of tissue. In particular embodiments, the regulatory sequence can result in the constitutive expression of the one or more therapeutic proteins upon entry of the vector into the cell. Alternatively, the regulatory sequences can include inducible sequences. Inducible regulatory sequences are well known to those skilled in the art and are those sequences that require the presence of an additional inducing factor to result in expression of the one or more therapeutic proteins. Examples of suitable regulatory sequences include binding sites corresponding to tissue-specific transcription factors based on endogenous nuclear proteins, sequences that direct expression in a specific cell type, the lac operator, the tetracycline operator, and the steroid hormone operator. Any inducible regulatory sequence known to those of skill in the art may be used.
[0051] In particular embodiments, viral vectors are coupled to magnetic particles to form a complex. Magnetic particles refer to magnetically responsive solid phases which are particles or aggregates thereof of micro- to nanometer-ranged size which contain one or more metals or oxides or hydroxides thereof, that react to magnetic force upon the influence of a magnetic field, preferably resulting in an attraction towards the source of the magnetic field or in the acceleration of the particle in a preferred direction of space. Magnetic can refer to temporarily magnetic materials, such as ferrimagnetic or ferromagnetic materials. The term, however, also encompasses paramagnetic and superparamagnetic materials. For example, magnetic nanoparticles include inorganic, polymeric, virus-like particles VLP(s), liposome, and selfassembling protein nanoparticles. Magnetic particles are commercially available from a number of sources, including, for example, Dynabeads, MACS microbeads, ViroMag Stem Transduction enhancer, and the like. In some aspects, the beads may be biodegradable. In other aspects, the
beads may be removed during the process. Because association with vectors can be achieved by a variety of processes, no very specific requirements are imposed on particle shape and size. In some aspects, the magnetic beads may be between 50nm to 500 micrometers, 100nm to 400 micrometers, 200nm to 200 micrometers, 300nm to 100 micrometers, or any subset thereof.
[0052] Magnetic particles can be made of one or more materials including ferro-, ferri-, or superparamagnetic compounds, such as iron, cobalt, or nickel, magnetic iron oxides or hydroxides such as Fe3O4, gamma-Fe2O3 or double oxides/hydroxides of two- or three-valent iron with two- or three-valent other metal ions or mixtures of the mentioned oxides or hydroxides. [0053] Magnetic colloidal iron oxide/hydroxide particles are prepared by precipitation from an acidic iron(ll)/iron(lll)-salt solution upon the addition of bases.
[0054] In one example, iron oxide/hydroxide particles are derived upon the addition of equivalent amounts of alkali carbonates (sodium hydrogencarbonate, sodium carbonate, and/or ammonium carbonate) to an acidic iron(ll)/iron(lll) salt solution followed by thermal oxidation to magnetic iron hydroxide and further on to iron oxide. The final particle size can be adjusted by thermal control of reaction velocity and by choosing appropriate concentrations of the reactants. Thus, small diameter particles of 20 -100 nm are obtained by timely separated formation of iron (II, III)- carbonate at temperatures of 1-50 °C, preferably at 5-10 °C and subsequent heating. Larger particles of 100 - 1000 nm are obtained at reaction temperatures of 60-100 °C implying a faster transformation of iron(ll,lll)-carbonate to iron(ll,lll)-hydroxide.
[0055] Nano-crystalline magnetic particles from double-oxides or hydroxides of two- or three- valent iron with two- or three-valent metal ions other than iron or mixtures of the corresponding oxides or hydroxides can also be prepared according to the above-mentioned procedures by using a salt solution of the two- or three-valent metals. Magnetic double oxides or- hydroxides of the three-valent iron are preferentially prepared with two-valent metal ions selected from the first row of transition metals (such as Co(ll), Mn(ll), Cu(ll) or Ni(ll)), whereas magnetic double oxides or-hydroxides of the two-valent iron are preferentially prepared with three-valent metal ions such as Cr(lll), Gd(lll), Dy(lll) or Sm(lll).
[0056] In particular embodiments, the magnetic particles are iron oxide particles.
[0057] In particular embodiments, magnetic particles have a size (i.e. a maximal extension) of up to 2000 nm, up to 1500 nm, up to 1000 nm, up to 800 nm, or up to 600 nm.
[0058] Magnetic particles can be coated with positively or negatively charged electrolytes, such as phosphates, citrates or amines; silanes; fatty acids; or polymers, such as polysaccharides, polyamino acids, proteins or synthetic polymers. These coating compounds can have reactive or derivatizable functional groups or these can be introduced by chemical modification after the
coating process.
[0059] Functional groups can have cation exchange properties such as found in xanthate-, xanthide, dicarboxyl-, carboxy methyl-, sulfonate-, sulfate-, triacetate-, phosphonate-, phosphate- , citrate-, tartrate-, carboxylate-, or lactate groups of naturally occurring or synthetic polymers. Alternatively, these functional groups can be introduced into natural and synthetic polymers prior to coating or after coating of magnetic particles. Examples of naturally occurring polymers are polysaccharides such as starch, dextran, glycosaminoglycans, agar, gum-gatti or gum-guar or analogues thereof. Suitable derivatives of synthetic polymers can be based on poly(vinyl alcohol) or poly(vinylpyrrolidone) or polyethylene glycole), poly(lactic acid), poly(lactic-co-glycolic acid) or poly(caprolactone). Also, proteins like casein, collagen, gelatin, albumin, or analogous derivatives thereof are useful coating compounds. Other examples of suitable polymers with ion exchange characteristics are polyacrylic acids, poly(styrene sulfonic acid), poly(vinylphosphoric acid) or polymeric arabinic acid, alginate, pectin or polyaspartic or polyglutamic acid.
[0060] Anion-exchange polymers carry endstanding or internal primary-, secondary amino-, imino-, tertiary amino- or quarternary ammonium groups, such as amino-, alkylamine, dietylaminoethyl-, triethylaminoethyl-, trimethylbenzylammonium-groups. Again, these polymers can be of natural or synthetic origin and the cationic functional groups can be inherent or can be grafted by synthetic methods prior to or after coating of magnetic particles. Examples include polysaccharides, proteins, or synthetic polymers and derivates thereof such as chitosan, poly(lysine), polyethylene imine), poly(amine), poly(diallyldimethylammonium) or poly(vinylpyridine).
[0061] Functional groups for covalent coupling can be inherent in such polymers or can be introduced by synthetic methods well known to the one skilled in the art of synthetic chemistry. Examples are aldehyde, diazo, carbodiimide, dichlortriazine, alkyl halogenide, imino carbonate, carboxyl, amino, hydroxyl, or thiol groups.
[0062] In particular embodiments, the magnetic particles are coupled with one or more oligo- or polycations or oligo- or polyanions.
[0063] In particular embodiments, said oligo- or polycation or oligo- or polyanion is a compound selected from the group consisting of poly(ethylene imine) (PEI), PEI-streptavidin, PEI-biotin, starch-phosphate, polyaspartic acid, polyacrylic acid, polyacrylic-co-maleic acid and arabinic acid. PEI as well as other compounds mentioned to be useful for coating the magnetic particles may be modified. Examples include PEI-ethoxylated (a monolayer of PEI coating the magnetic particle being ethoxylated), PEI-epichlorhydrin (PEI modified with epichlorhydrin) or PEI-sodium dodecyl sulfate (PEI modified by a covalent coupling of sodium dodecyl sulfate (SDS) by carbodiimide
activation (N-Ethyl-N'-(dimethylaminopropyl)-carbodiimide).
[0064] A complex refers to a finite entity including one or more vector(s) and one or more magnetic particle(s), which are suited for being brought in contact with cells in order to transfect them. The ratio of vector and magnetic particles in a complex may vary. For example, the ratios may be 1 :50, 1 :100, 1 :250: 1 :500, 1 :750, 1 :1000, and the like. While these ratios may be in different volumes, in some aspects the working solution has a volume of 50pL. In some aspects, the ratio of vector to magnetic particle may vary with cell density, target dose of vector, and/or the titer of the vector.
[0065] In particular embodiments, the linkage within a complex between a magnetic particle(s) and a vector(s) is by physical linkage, chemical linkage, or by biological interaction.
[0066] Physical linkage, chemical linkage, or biological interaction includes electrostatic interaction, hydrophobic interaction, hydrophilic interaction, receptor-ligand type interaction, such as biotin-streptavidin or antigen-antibody binding, or lectin-type binding, and interaction of natural or synthetic nucleic acids, such as sequence-specific hybridization, triple helix formation, peptidenucleic acid-nucleic acid interaction and the like. Any combination of the above indicated interactions can be used, including particle/precipitate formation induced by such interactions.
[0067] In particular embodiments, the magnetic particles can be linked to a vector by a covalent linkage. Exemplary linkages include amide, ester, thioester, ether, thioether, or disulfide bonds. The linkage can be direct by reacting functional groups of the surface coating of the magnetic particle with functional groups of the vector or by using a homo- or hetero-bifunctional linker molecule. The linker molecule can also contain a spacer arm consisting of an alkyl chain or of linear or branched, natural or synthetic polymers such as peptides, proteins, polyethylene glycols, or carbohydrates (e.g., glycosaminoglycans, chitosans, starch). The preparation of the complexes comprising one or more magnetic particles and one or more vectors may be achieved by any of the methods common to the person skilled in the art and available from the literature. For example, for vector assembly, the process of salt-induced aggregation, a phenomenon well-known in colloid science, may be exploited: Colloidal systems with charged surfaces tend to aggregate (flocculate) due to over-compensation of repulsive (electrostatic) forces by attractive forces upon increasing the ionic strength. This process requires mixing components in salt-containing solvent or mixing in salt-free solvents, followed by addition of salt.
[0068] A complex can also be prepared by biologically linking magnetic particles to the vector via biotin-streptavidin interactions. For example, magnetic particles coated with PEI-streptavidin may be added to a vector coupled to PEI-biotin. Similarly, magnetic particles can be connected with vectors using antigen-antibody interactions.
[0069] A further process for preparing a complex is to perform a calcium-phosphate coprecipitation of a vector with magnetic particles.
[0070] Transfection refers to a process of introducing one or more foreign nucleic acid molecule(s) into a cell. Foreign may refer to (a) nucleic acid molecule(s) which is/are not part of the genome of the cell nor of any other nucleic acid molecule being present in the cell before said transfection such as extrachromosomal DNA, plasmids, cosmids, or artificial chromosomes including viral vectors. Likewise, foreign can refer to nucleic acid molecules that are, at least partially, homologous with respect to the target cell, however, occur in the vector in a different molecular environment than those naturally occurring in the cell. Such homologous nucleic acid molecules include, e.g., overexpression or antisense constructs. The terms MAT and magnetofection refer to transfection using complexes of magnetic particle(s) and vector(s) using the application of a magnetic field.
[0071] A suitable magnetic field refers to magnetic fields that, with regard to the shape of the field and its strength, are suited for attracting the above-described complexes against other forces acting on the complexes, such as diffusion or hydrodynamic forces. Suitable magnetic fields generally have an intensity of more than 0.5 Tesla or more than 1 Tesla.
[0072] Magnetic fields can be permanent fields or an electromagnetic fields. Permanent fields refer to magnetic fields which are generated by a permanent magnet. Examples of suitable permanent magnets include high energy, permanent magnets, e.g., made of materials containing neodym. Such permanent magnets may be constructed as arrays, as yoke and magnetic return path, or in aperture or sandwich configurations. The intensity may be controlled with a suitable measuring instrument such as a Hall probe.
[0073] Electromagnetic fields refer to magnetic fields which are generated by electric current. Applicable examples include nuclear magnetic resonance tomographs. Such devices may be used for generating the field and for diagnosing, supervising, and documenting the distribution and local enrichment of the complexes applied.
[0074] Electromagnetic fields can oscillate. Oscillation refers to magnetic fields that periodically change direction. Such an oscillation may induce kinetic energy in the complexes which may be useful in cases where the vectors are released from the complex and the movement promotes its diffusion.
[0075] Magnetic fields may be applied for a variety of lengths of time. For example, magnetic fields may be applied for 1 minute to 1 hour, 5 minutes to 45 minutes, 10 minutes to 40 minutes, 15 minutes to 35 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes or any fraction thereof.
[0076] Traditionally, cells are transduced multiple times with 20-100 transducing units per cell for two to four days. The provided method can use less than half of the conventional amount of transducing units. For example, the use of MAT allows for decreased amounts of transducing units to be used and decreased time for transfection, allowing decreased costs. In some aspects, fewer than 19, fewer than 15, fewer than 10, or fewer than 5, transducing units per cell may be combined with each cell population. The cells of interest and the viral vector combination can be placed over a magnet for an amount of time. Such an amount of time may be 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 1 hour, and the like. In some aspects, the cells are extracted and enriched in realtime during collection, allowing for fewer patient visits and decreasing delays in treatment. In some aspects, cell enrichment and MAT may take place simultaneously.
[0077] In particular embodiments, the transfected nucleic acid is stably integrated into the genome of a cell. In particular embodiments, the nucleic acid is stably maintained in a cell as a separate, episomal segment.
[0078] In particular embodiments, the efficiency of integration, the size of the DNA sequence that can be integrated, and the number of copies of a DNA sequence that can be integrated into a genome can be improved by using transposons. Transposons or transposable elements include a short nucleic acid sequence with terminal repeat sequences upstream and downstream. Active transposons can encode enzymes that facilitate the excision and insertion of nucleic acid into a target DNA sequence.
[0079] A number of transposable elements have been described in the art that facilitate the insertion of nucleic acids into the genome of vertebrates, including humans. Examples include sleeping beauty (e.g., derived from the genome of salmonid fish); piggyback (e.g., derived from lepidopteran cells and/or the Myotis lucifugus); mariner (e.g., derived from Drosophila); frog prince (e.g., derived from Rana pipiens); Tol2 (e.g., derived from medaka fish); TcBuster (e.g., derived from the red flour beetle Tribolium castaneum) and spinON. CRISPR-Cas systems may also be used.
[0080] In particular embodiments, transduced cells can be cultured before final formulation for, for example, 6 hours, 12 hours, 24 hours, 36 hours, 48 hours, 56 hours, 65 hours, 72 hours, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, or 15 days.
[0081] The transduced cells can then be harvested and washed to provide a transduced cell product. The transduced cell product may then by formulated for reinfusion. Exemplary carriers include saline, buffered saline, physiological saline, water, Hanks' solution, Ringer's solution,
Nonnosol-R (Abbott Labs), Plasma-Lyte A® (Baxter Laboratories, Inc., Morton Grove, IL), glycerol, ethanol, and combinations thereof.
[0082] Therapeutically effective amounts of cells within formulations can be greater than 102 cells, greater than 103 cells, greater than 104 cells, greater than 105 cells, greater than 106 cells, greater than 107 cells, greater than 108 cells, greater than 109 cells, greater than 1010 cells, or greater than 1011.
[0083] In formulations disclosed herein, cells are generally in a volume of a liter or less, 500 mis or less, 250 mis or less, or 100 mis or less. Hence the density of administered cells is typically greater than 104 cells/ml, 107 cells/ml, or 108 cells/ml.
[0084] The formulations disclosed herein can be prepared for administration by, for example, injection, infusion, perfusion, or lavage.
[0085] Methods disclosed herein include producing cells for and/or treating subjects (humans, veterinary animals (dogs, cats, reptiles, birds, etc.), livestock (horses, cattle, goats, pigs, chickens, etc.), and research animals (monkeys, rats, mice, fish, etc.) with genetically-modified cells disclosed herein. Treating subjects includes delivering therapeutically effective amounts. Therapeutically effective amounts include those that provide effective amounts, prophylactic treatments, and/or therapeutic treatments.
[0086] An “effective amount” is the number of cells necessary to result in a desired physiological change in a subject. Effective amounts are often administered for research purposes.
[0087] A "prophylactic treatment" includes a treatment administered to a subject who does not display signs or symptoms of a condition to be treated or displays only early signs or symptoms of the condition to be treated such that treatment is administered for the purpose of diminishing, preventing, or decreasing the risk of developing the condition. Thus, a prophylactic treatment functions as a preventative treatment against a condition.
[0088] A "therapeutic treatment" includes a treatment administered to a subject who displays symptoms or signs of a condition and is administered to the subject for the purpose of reducing the severity or progression of the condition.
[0089] The actual dose amount administered to a particular subject can be determined by a physician, veterinarian, or researcher taking into account parameters such as physical and physiological factors including target; body weight; type of condition; severity of condition; upcoming relevant events, when known; previous or concurrent therapeutic interventions; idiopathy of the subject; and route of administration, for example. In addition, in vitro and in vivo assays can optionally be employed to help identify optimal dosage ranges.
[0090] Therapeutically effective amounts to administer can include greater than 102 cells, greater
than 103 cells, greater than 104 cells, greater than 105 cells, greater than 106 cells, greater than 107 cells, greater than 108 cells, greater than 109 cells, greater than 1010 cells, or greater than 1011. In particular embodiments, a minimum dose is 1 x 106 cells/kg. In particular embodiments, a minimum dose is 2X106 cells/kg subject body weight.
[0091] As indicated, the compositions and formulations disclosed herein can be administered by, for example, injection, infusion, perfusion, or lavage and can more particularly include administration through one or more bone marrow, intravenous, intradermal, intraarterial, intranodal, intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intratumoral, intramuscular, intravesicular, and/or subcutaneous infusions and/or bolus injections.
[0092] In some aspects, the reinfusion formula may be administered to the patient prior to the clearance of a mobilization agent. In particular embodiments, the reinfusion formula may be administered to the patient on the same day as the administration of the mobilization agent or on the same day as MAT. Thus, the provided methods allow for the use of a decreased number of transducing units, decreased time for transfection, and decreased patient visits for treatment.
[0093] Any nucleic acid including a therapeutic gene can be introduced into target cells disclosed herein. The term “gene” refers to a nucleic acid sequence (used interchangeably with polynucleotide or nucleotide sequence) that encodes one or more therapeutic proteins as described herein. This definition includes various sequence polymorphisms, mutations, and/or sequence variants wherein such alterations do not substantially affect the function of the encoded one or more therapeutic proteins. The term “gene” may include not only coding sequences but also regulatory regions such as promoters, enhancers, and termination regions. The term further can include all introns and other DNA sequences spliced from the mRNA transcript, along with variants resulting from alternative splice sites. Gene sequences encoding the molecule can be DNA or RNA that directs the expression of the one or more therapeutic proteins. These nucleic acid sequences may be a DNA strand sequence that is transcribed into RNA or an RNA sequence that is translated into protein. The nucleic acid sequences include both the full-length nucleic acid sequences as well as non-full-length sequences derived from the full-length protein. The sequences can also include degenerate codons of the native sequence or sequences that may be introduced to provide codon preference in a specific cell type.
[0094] A gene sequence encoding one or more therapeutic proteins can be readily prepared by synthetic or recombinant methods from the relevant amino acid sequence. In particular embodiments, the gene sequence encoding any of these sequences can also have one or more restriction enzyme sites at the 5' and/or 3' ends of the coding sequence in order to provide for
easy excision and replacement of the gene sequence encoding the sequence with another gene sequence encoding a different sequence. In particular embodiments, the gene sequence encoding the sequences can be codon optimized for expression in mammalian cells.
[0095] As one example, a gene can be selected to provide a therapeutically effective response against a condition that, in particular embodiments, is inherited. In particular embodiments, the condition can be Grave’s Disease, rheumatoid arthritis, pernicious anemia, Multiple Sclerosis (MS), inflammatory bowel disease, systemic lupus erythematosus (SLE), adenosine deaminase deficiency (ADA-SCID) or severe combined immunodeficiency disease (SCID), Wiskott-Aldrich syndrome (WAS), chronic granulomatous disease (CGD), Fanconi anemia (FA), Battens disease, adrenoleukodystrophy (ALD) or metachromatic leukodystrophy (MLD), muscular dystrophy, pulmonary aveolar proteinosis (PAP), pyruvate kinase deficiency, Shwachmann-Diamond- Blackfan anemia, dyskeratosis congenita, cystic fibrosis, Parkinson’s disease, Alzheimer’s disease, or amyotrophic lateral sclerosis (Lou Gehrig’s disease). In particular embodiments, depending on the condition, the therapeutic gene may be a gene that encodes a protein and/or a gene whose function has been interrupted. Exemplary therapeutic gene and gene products include: soluble CD40; CTLA; Fas L; antibodies to CD4, CD5, CD7, CD52, etc.; antibodies to IL1 , IL2, IL6; an antibody to TOR specifically present on autoreactive T cells; IL4; IL10; IL12; IL13; IL1 Ra, SIL1 RI, SIL1 RII; sTNFRI; sTNFRII; antibodies to TNF; P53, PTPN22, and DRB1*1501/DQB1*0602; globin family genes; WAS; phox; FANC family genes; dystrophin; pyruvate kinase; CLN3; ABCD1 ; arylsulfatase A; SFTPB; SFTPC; NLX2.1 ; ABCA3; GATA1 ; ribosomal protein genes; TERT; TERC; DKC1 ; TINF2; CFTR; LRRK2; PARK2; PARK7; PINK1 ; SNCA; PSEN1 ; PSEN2; APP; SOD1; TDP43; FUS; ubiquilin 2; and/or C9ORF72. Therapeutically effective amounts may provide function to immune and other blood cells and/or microglial cells or may alternatively - depending on the treated condition - inhibit lymphocyte activation, induce apoptosis in lymphocytes, eliminate various subsets of lymphocytes, inhibit T cell activation, eliminate or inhibit autoreactive T cells, inhibit Th-2 or Th-1 lymphocyte activity, antagonize IL1 or TNF, reduce inflammation, induce selective tolerance to an inciting agent, reduce or eliminate an immune-mediated condition; and/or reduce or eliminate a symptom of the immune-mediated condition. Therapeutic effective amounts may also provide functional DNA repair mechanisms; surfactant protein expression; telomere maintenance; lysosomal function; breakdown of lipids or other proteins such as amyloids; permit ribosomal function; and/or permit development of mature blood cell lineages which would otherwise not develop such as macrophages other white blood cell types.
[0096] As another example, a gene can be selected to provide a therapeutically effective
response against diseases related to red blood cells and clotting. In particular embodiments, the disease is a hemoglobinopathy like thalassemia, or a sickle cell disease/trait. The therapeutic gene may be, for example, a gene that induces or increases production of hemoglobin; induces or increases production of beta-globin, or alpha-globin; or increases the availability of oxygen to cells in the body. The therapeutic gene may be, for example, HBB or CYB5R3. Exemplary effective treatments may, for example, increase blood cell counts, improve blood cell function, or increase oxygenation of cells in patients. In another particular embodiment, the disease is hemophilia. The therapeutic gene may be, for example, a gene that increases the production of coagulation/clotting factor VIII or coagulation/clotting factor IX, causes the production of normal versions of coagulation factor VIII or coagulation factor IX, a gene that reduces the production of antibodies to coagulation/clotting factor VI II or coagulation/clotting factor IX, or a gene that causes the proper formation of blood clots. Exemplary therapeutic genes include F8 and F9. Exemplary effective treatments may, for example, increase or induce the production of coagulation/clotting factors VIII and IX; improve the functioning of coagulation/clotting factors VIII and IX, or reduce clotting time in subjects.
[0097] As another example, a gene can be selected to provide a therapeutically effective response against a lysosomal storage disorder. In particular embodiments, the lysosomal storage disorder is mucopolysaccharidosis (MPS), type I; MPS II or Hunter Syndrome; MPS III or Sanfilippo syndrome; MPS IV or Morquio syndrome; MPS V; MPS VI or Maroteaux-Lamy syndrome; MPS VII or sly syndrome; alpha-mannsidosis; beta-mannosidosis; glycogen storage disease type I , also known as GSDI , von Gierke disease, or T ay Sachs; Pompe disease; Gaucher disease; Fabry disease. The therapeutic gene may be, for example, a gene encoding or inducing production of an enzyme, or that otherwise causes the degradation of mucopolysaccharides in lysosomes. Exemplary therapeutic genes include IDUA or iduronidase, IDS, GNS, HGSNAT, SGSH, NAGLU, GUSB, GALNS, GLB1 , ARSB, and HYAL1. Exemplary effective genetic therapies for lysosomal storage disorders may, for example, encode or induce the production of enzymes responsible for the degradation of various substances in lysosomes; reduce, eliminate, prevent, or delay the swelling in various organs, including the head (exp. Macrosephaly), the liver, spleen, tongue, or vocal cords; reduce fluid in the brain; reduce heart valve abnormalities; prevent or dilate narrowing airways and prevent related upper respiratory conditions like infections and sleep apnea; reduce, eliminate, prevent, or delay the destruction of neurons, and/or the associated symptoms.
[0098] As another example, a gene can be selected to provide a therapeutically effective response against a hyperproliferative disease. In particular embodiments, the hyperproliferative
disease is cancer. The therapeutic gene may be, for example, a tumor suppressor gene, a gene that induces apoptosis, a gene encoding an enzyme, a gene encoding an antibody, or a gene encoding a hormone. Exemplary therapeutic genes and gene products include 101 F6, 123F2 (RASSF1), 53BP2, abl, ABLI, ADP, aFGF, APC, ApoAl, ApoAIV, ApoE, ATM, BAI-1 , BDNF, Beta*(BLU), bFGF, BLC1 , BLC6, BRCA1 , BRCA2, CBFA1 , CBL, C-CAM, CFTR, CNTF, COX-1 , CSFIR, CTS-1 , cytosine deaminase, DBCCR-1 , DCC, Dp, DPC-4, E1A, E2F, EBRB2, erb, ERBA, ERBB, ETS1 , ETS2, ETV6, Fab, FCC, FGF, FGR, FHIT, fms, FOX, FUS 1 , FUS1, FYN, G-CSF, GDAIF, Gene 21 (NPRL2), Gene 26 (CACNA2D2), GM-CSF, GMF, gsp, HCR, HIC-1 , HRAS, hst, IGF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11 IL-12, ING1 , interferon a, interferon p, interferon y, IRF-1 , JUN, KRAS, LCK, LUCA-1 (HYAL1), LUCA-2 (HYAL2), LYN, MADH4, MADR2, MCC, mda7, MDM2, MEN-I, MEN-II, MLL, MMAC1 , MYB, MYC, MYCL1 , MYCN, neu, NF-1 , NF-2, NGF, NOEY1 , NOEY2, NRAS, NT3, NT5, OVCA1 , p16, p21 , p27, p53, p57, p73, p300, PGS, PIM1, PL6, PML, PTEN, raf, Rap1A, ras, Rb, RB1 , RET, rks-3, ScFv, scFV ras, SEM A3, SRC, TAL1 , TCL3, TFPI, thrombospondin, thymidine kinase, TNF, TP53, trk, T- VEC, VEGF, VHL, WT1 , WT-1 , YES, and zac1. Exemplary effective genetic therapies may suppress or eliminate tumors, result in a decreased number of cancer cells, reduced tumor size, slow or eliminate tumor growth, or alleviate symptoms caused by tumors.
[0099] As another example, a gene can be selected to provide a therapeutically effective response against an infectious disease. In particular embodiments, the infectious disease is human immunodeficiency virus (HIV). The therapeutic gene may be, for example, a gene rendering immune cells resistant to HIV infection, or which enables immune cells to effectively neutralize the virus via immune reconstruction, polymorphisms of genes encoding proteins expressed by immune cells, genes advantageous for fighting infection that are not expressed in the patient, genes encoding an infectious agent, receptor or coreceptor; a gene encoding ligands for receptors or coreceptors; viral and cellular genes essential for viral replication including; a gene encoding ribozymes, antisense RNA, small interfering RNA (siRNA) or decoy RNA to block the actions of certain transcription factors; a gene encoding dominant negative viral proteins, intracellular antibodies, intrakines, and suicide genes. Exemplary therapeutic genes and gene products include a2 1 ; av[33; av[35; avp63; BOB/GPR15; Bonzo/STRL-33/TYMSTR; CCR2; CCR3; CCR5; CCR8; CD4; CD46; CD55; CXCR4; aminopeptidase-N; HHV-7; ICAM; ICAM-1 ; PRR2/HveB; HveA; a-dystroglycan; LDLR/a2MR/LRP; PVR; PRR1/HveC; and laminin receptor. A therapeutically effective amount for the treatment of HIV, for example, may increase the immunity of a subject against HIV, ameliorate a symptom associated with AIDS or HIV, or induce an innate or adaptive immune response in a subject against HIV. An immune response against
HIV may include antibody production and result in the prevention of AIDS and/or ameliorate a symptom of AIDS or HIV infection of the subject, or decrease or eliminate HIV infectivity and/or virulence.
[0100] Bacteria are also encompassed in the term infectious agent. Other infectious agents include, for example, parasites such as members of the Plasmodium genus, the agent that causes malaria. Exemplary therapeutic genes affecting the infectivity of parasites include erythrocyte skeletal protein 4.1, glycophorin, p55, and the Duffy allele, which encodes a chemokine receptor. Therapeutically effective amounts will, for example, reduce or eliminate the infectious disease or agent. They may also reduce or eliminate a symptom of the infectious disease or agent.
[0101] The genetically-modified cell can be any cell type capable of ex vivo enrichment, modification, and formulation as described herein. Exemplary cell types include HSPC positive for one or more of CD34, CD43, CD45RO, CD45RA, CD59, CD90, CD109, CD117, CD133, CD166, HLA D or negative for Lin or CD38; T cells (e.g., a|3 T cells, y8 Tcells, mature T cells (e.g., CD3+), activated T cells (e.g., 4-1 BB+ (CD137+)), helper T cells (e.g., CD4+), cytotoxic T-cells (e.g., CD8+), central memory T-cells (TCM, e.g., CD62L+ CD25+, CD127+, or CCR7+ and CD45RO+/CD45RA- as compared to naive cells), effector memory T cells (TEM, e.g., CD62L-, CD45RA- as compared to a naive cell), regulatory T cells (TREG, e.g., CD25+, CTLA-4+, GITR+, GARP+, and LAP+), naive T-cells (e.g., non-antigen experienced T cell that expresses CD62L and CD45RA, and does not express CD45RO as compared to central or effector memory cells), natural killer cells (also known as NK cells, K cells, and killer cells, e.g., CD8+, CD16+, CD56+, CD3-, macrophages, monocytes, B cells, among others.
[0102] Current gene therapy methods require the use of a clean room meeting ISO 5 standards or lower. Clean rooms are rated according to the quantity and size of particles per cubic meters of air. The International Standards Organization (ISO) clean room standard includes classes: ISO 1 , ISO 2, ISO 3, ISO 4, ISO 5, ISO 6, ISO 7, ISO 8, and ISO 9 with ISO 1 being the cleanest end of the scale.
[0 03] An ISO class 4 clean room allows up to 10,000 0.1-pm-sized particles per cubic meter and requires an average airflow velocity of 0.254 - 0.457 meters/second (or 50 - 90 ft/min), 300 - 540 air changes per hour, fan/filter unit (FFU) coverage of 50 - 90%, ULPA filters, and a test particle count every 6 months and an airflow and air-pressure differential every 12 months.
[0104] An ISO class 5 clean room allows up to 100,000 0.1 -pm-sized particles per cubic meter of air and requires an average airflow velocity of 0.203 - 0.406 meters/second (or 40 - 80 ft/min), 240 - 480 Air changes per hour, FFU coverage of 35 - 70%, and a test particle count every 6 months, and airflow and air-pressure differential every 12 months.
[0105] An ISO class 6 clean room allows up to 1 ,000,000 0.1-pm-sized particles per cubic meter and requires an average airflow velocity of 0.127 - 0.203 meters/second (or 25 - 40 ft/min), 150 - 240 air changes per hour, FFU coverage of 25 - 40%, and a test particle count, airflow, and air- pressure differential every 12 months.
[0106] An ISO class 7 clean room allows up to 352,000 0.5-pm-sized particles per cubic meter and requires an average airflow velocity of 0.051 - 0.076 meters/second (or 10 - 15 ft/min), 60 - 90 air changes per hour, FFU coverage of 15 - 20%, and a test particle count, airflow, and air- pressure differential every 12 months.
[0107] An ISO class 8 clean room allows up to 3,520,000 0.5-pm sized particles per cubic meter and requires an average airflow velocity of 0.005 - 0.041 meters/second (or 1 - 8 ft/min), 5 - 48 air changes per hour, FFU coverage of 5- 15%, and a test particle count, airflow, and air-pressure differential every 12 months. The provided methods allow for the use of an ISO class 7 clean room, decreasing the requirements and expenses for gene therapy production.
[0108] Exemplary Kits: Also disclosed herein are kits including one or more containers including materials necessary or helpful to practice the platforms disclosed herein. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use, or sale for human administration.
[0109] Optionally, the kits described herein further include instructions for using the kit in the technologies disclosed herein. In various embodiments, the kit may include instructions regarding sample processing; software program use; user interface guidelines; administration of the genetically-modified and formulated cells; appropriate reference levels to interpret results associated when using the kit; proper disposal of the related waste; and the like. The instructions can be in the form of printed instructions provided within the kit or the instructions can be printed on a portion of the kit itself. Instructions may be in the form of a sheet, pamphlet, brochure, CD- Rom, or computer-readable device, or can provide directions to instructions at a remote location, such as a website.
[0110] Particular embodiments of kits include one or more of: one or more sterile tubing sets; saline solution for intravenous infusion (e.g., Plasmalyte A); 25% human serum albumin (HSA); 6% hetastarch in saline (HES); buffer (e.g., PBS/EDTA); biotinylated anti-CD34 antibody (clone 12.8) (also referred to as 12.8 antibody); CD34 microbeads or other direct-conjugate antibody- magnetic bead complex; GAMMAGARD (IVIg) or other blocking agent (e.g., autologous serum); streptavidin-coated microbeads; tunneled cryobag(s); needle-less spike adapter(s); syringe(s) (e.g., 60mL, 30ml_); concentrated lentivirus; medical gloves; gown and/or face mask. The kits may
exclude transduction media, cytokines, growth factors, and the like as noted above.
[0111] In particular embodiments, the kits exclude cyto- and/or chemokines, and small molecules or additional agents to promote cell survival and gene transfer. Particular embodiments exclude StemSpan SFEM or ACF media (both from Stem Cell Technologies) or XVivo media types (Lonza). Particular embodiments exclude recombinant human granulocyte colony stimulating factor (G-CSF), stem cell factor (SCF), thrombopoietin (TPO), flightless 3 ligand (flt3 or flt3L), and interleukins such as interleukin 3 (IL3), interleukin 6 (IL6). Particular embodiments exclude arylhydrocarbon receptor antagonists (e g., StemRegeninl (e.g., Phenol, 4-[2-[[2-benzo[b]thien-3-yl- 9-(1-methylethyl)-9H-purin-6-yl]amino]ethyl]); GNF351 (e.g., N-(2-(3H-lndol-3-yl)ethyl)-9- isopropyl-2-(5-methyl-3-pyridyl)-7H-purin-6-amine,N-(2-(1 H-lndol-3-yl)ethyl)-9-isopropyl- 2-(5- methylpyridin-3-yl)-9H-purin-6-amine); CH223191 (e.g., 1-Methyl-/V-[2-methyl-4-[2-(2- methylphenyl)diazenyl]phenyl-1H-pyrazole-5-carboxamide), pyrimidoindole derivatives (e.g., UM171 (e.g., (1r,4r)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4- yl)cyclohexane-1 ,4-diamine); UM729 (Methyl 4-((3-(piperidin-1-yl)propyl)amino)-9H- pyrimido[4,5-b] indole-7-carboxylate); UM118428 (e.g., Tranylcypromine HCI, (trans-2- Phenylcyclopropylamine hydrochloride)), glucocorticoid receptor antagonists (mifepristone (e.g., RU-486), RU-43044, Miconazole, 11-oxa cortisol, 11-oxa prednisolone, and Dexamethasone mesylate.
[0112] An independent, greatly simplified workflow was developed with a functionally closed system which enables use of an ISO class 7 clean room facility and eliminates the need for culture of cells to facilitate transduction. This workflow can be completed in less than 1 day, greatly reducing the time, materials and reagents required for patient-specific product manufacturing. This workflow leverages different off-the-shelf technology for washing and preparation of cells for immunomagnetic bead-based separation. Target cells are then purified by a manual, magnetic separation which is combined with simultaneous magnetically-assisted transduction (MAT) requiring less than 1/2 the typical volume of lentiviral vector supernatant required in standard processes. The proof-of-concept for this workflow has been demonstrated with a lentiviral vector encoding a fluorescent reporter transgene for easy monitoring by flow cytometry.
[0113] The Exemplary Embodiments and Examples below are included to demonstrate particular embodiments of the disclosure. Those of ordinary skill in the art should recognize in light of the present disclosure that many changes can be made to the specific embodiments disclosed herein and still obtain a like or similar result without departing from the spirit and scope of the disclosure. 1. A method including: obtaining a cell population including target cells,
exposing the cell population to target-cell enriching magnetic beads, contacting the target cells with vector-magnetic bead complexes, and applying a magnetic field to the target cells resulting in transduction of the target cells with the vector.
2. The method of embodiment 1 , wherein the method does not utilize culture media during the transduction.
3. The method of embodiments 1 or 2, wherein the method does not utilize exogenous cytokines.
4. The method of any of embodiments 1-3, wherein vector is at an amount of 10 infectious particles per cell in the cell population.
5. The method of any of embodiments 1-3, wherein vector is at an amount of 10 infectious particles per target cell in the cell population.
6. The method of any of embodiments 1-3, wherein vector is at an amount of 5-15 infectious particles per cell in the cell population.
7. The method of any of embodiments 1-3, wherein vector is at an amount of 5-15 infectious particles per target cell in the cell population.
8. The method of any of embodiments 1-7, wherein the magnetic field is applied for 5-45 minutes.
9. The method of any of embodiments 1-8, wherein the magnetic field is applied for 15-35 minutes.
10. The method of any of embodiments 1-9, wherein the magnetic field is applied for 30 minutes.
11. The method of any of embodiments 1-10, wherein timing of the exposing, contacting, and applying overlaps.
12. The method of any of embodiments 1-10, wherein the exposing occurs before the contacting and applying.
13. The method any of embodiments 1-12, wherein the obtaining the cell population includes collecting blood or bone marrow.
14. The method of any of embodiments 1-12, further including administering a mobilizer to a subject before the obtaining.
15. The method of embodiment 14, wherein the mobilizer includes granulocyte colony stimulating factor (G-CSF).
16. The method of any of embodiments 1-15, wherein the target cells include stem cells.
17. The method of embodiment 16, wherein the stem cells include hematopoietic stem cells.
18. The method of any of embodiments 1-15, wherein the target cells include immune cells.
19. The method of embodiment 18, wherein the immune cells include T cells or B cells.
20. The method of any of embodiments 1-19, wherein the target-cell enriching magnetic beads include a magnetic bead and a binding domain that binds the target cells.
21. The method of any of embodiments 1-20, wherein the vector-magnetic bead complexes include a magnetic bead and a vector.
22. The method of any of embodiments 1-21 , wherein the vector includes a viral vector.
23. The method of embodiment 22, wherein the viral vector includes a lentiviral vector.
24. The method of any of embodiments 1-23, further including formulating a cell product for administration to a subject after the applying.
25. The method of embodiment 24, further including evaluating quality and sterility of the cell product.
26. The method of embodiment 24, further including administering the cell product to the subject.
27. The method of embodiment 26, wherein the subject was administered a mobilizer within 48 hours of the administering of the cell product.
28. The method of embodiment 26, wherein the subject was administered a mobilizing agent within 48 hours of the administering of the cell product.
29. The method of any of embodiments 1-20, wherein the method is performed in an International Standards Organization (ISO) level 7 clean room.
30. A method of providing ex vivo gene therapy to a subject in need thereof including: collecting a cell population from the subject wherein the cell population includes target cells, enriching the target cells in the cell population by exposing the cell population to target-cell enriching magnetic beads, applying a magnetic field to the cell population in the presence of vector-magnetic bead complexes thereby transducing the target cells, and formulating and administering transduced target cells to the subject.
31. The method of embodiment 30, wherein the subject does not receive chemotherapy between the collecting and the administering.
32. The method of embodiments 30 and 31 , wherein the method does not utilize culture media during the transducing.
33. The method of any of embodiments 30-32, wherein the method does not utilize exogenous cytokines during the transducing.
34. The method of any of embodiments 30-33, wherein vector is at an amount of 10 infectious
particles per cell in the cell population.
35. The method of any of embodiments 30-32, wherein vector is at an amount of 10 infectious particles per target cell in the cell population.
36. The method of any of embodiments 30-35, wherein vector is at an amount of 5-15 infectious particles per cell in the cell population.
37. The method of any of embodiments 30-35, wherein vector is at an amount of 5-15 infectious particles per target cell in the cell population.
38. The method of any of embodiments 30-37, wherein the magnetic field is applied for 5-45 minutes.
39. The method of any of embodiments 30-37, wherein the magnetic field is applied for 15-35 minutes.
40. The method of any of embodiments 30-37, wherein the magnetic field is applied for 30 minutes.
41. The method of any of embodiments 30-40, wherein timing of the exposing and applying overlaps.
42. The method of any of embodiments 30-40, wherein the exposing occurs before the applying.
43. The method of any of embodiments 30-42, wherein the collecting the cell population includes collecting blood or bone marrow.
44. The method of any of embodiments 30-43, further including administering a mobilizer to the subject before the collecting.
45. The method of embodiment 44, wherein the mobilizer includes granulocyte colony stimulating factor (G-CSF).
46. The method of embodiment any of embodiments 30-45, wherein the transduced target cells and the mobilizer are administered within 48 hours of each other.
47. The method of claim 44, wherein the transduced target cells and the mobilizer are administered within 24 hours of each other.
48. The method of any of embodiments 30-47, wherein the exposing, applying, and formulating occur in an International Standards Organization (ISO) level 7 clean room.
49. The method of any of embodiments 30-48, wherein the target cells include stem cells.
50. The method of embodiment 49, wherein the stem cells include hematopoietic stem cells.
51. The method of any of embodiments 30-49, wherein the target cells include immune cells.
52. The method of embodiment 51, wherein the immune cells include T cells or B cells.
53. The method of any of embodiments 30-52, wherein the target-cell enriching magnetic
beads include a magnetic bead and a binding domain that binds the target cells.
54. The method of any of embodiments 30-53, wherein the vector-magnetic bead complexes include a magnetic bead linked to a vector.
55. The method of embodiment 54, wherein the vector includes a viral vector.
56. The method of embodiment 55, wherein the viral vector includes a lentiviral vector.
57. The method of any of embodiments 30-56, further including harvesting and washing transduced target cells.
58. The method of any of embodiments 30-57, further including release testing of transduced target cells.
59. The method of any of embodiments 30-58, wherein there is no more than 24 hours between the collecting and the administering.
60. An apparatus including a docking unit, an entry port, and a magnet, wherein the docking unit includes an interface between the apparatus and a cell collection and/or manufacturing system.
[0114] EXAMPLE I. Comparison of standard culture based transduction, spinoculation, and MAT of CD34+ cells with cocal and VSV-G lentivirus. Healthy adult, CD34+ cells mobilized with G-CSF were obtained from four unique donors, 2 females and 2 males. The cells were transduced with either cocal virus envelope glycoprotein pseudotyped LV (cocal LC) or vesicular stomatitis virus envelope glycoprotein pseudotyped LV (VSV-G LV) encoding a green fluorescent protein (GFP) transgene using one of three transduction processes (1) standard culture-based transduction, (2) spinoculation, or (3) MAT.
[0115] The cells were slow-thawed at 37°C for 30 minutes. The cells were then stimulated for 16- 24 hours at 37°C and 5%CO2 in Stem Span™ SFEM II media containing recombinant human stem cell factor (SCF), thrombopoietin (TPO) and Fms-like tyrosinekinase 3 ligand (FLT3-L) at 100ng/ml each (Stemcell Technologies (Seattle, WA, USA)).
[0116] For culture, in each well of a 6-well tissue culture plate, cells were seeded at a density of 2x106 cells/ml of Stem Span™ SFEM II media containing vector at 10 transducing units (TU) per cell, recombinant human stem cell factor (SCF), thrombopoietin (TPO) and Fms-like tyrosinekinase 3 ligand (FLT3-L) at 100ng/ml each (Stemcell Technologies (Seattle, WA, USA)) and protamine sulfate at 8mg/ml (Fresenius Kabi, Lake Zurich, Switzerland). The cells were then incubated at 37°C, 5% CO2 for 24 hours. After 24 hours, cells were harvested and washed by centrifuging at 400g for 5 minutes. Cell pellets were resuspended in Iscove’s Modified Dulbecco’s medium containing 10% v/v heat-inactivated fetal bovine serum and recombinant human stem cell factor (SCF), thrombopoietin (TPO) and Fms-like tyrosinekinase 3 ligand (FLT3-L) at
100ng/ml each (Stemcell Technologies (Seattle, WA, USA)) and cultured for another 9 days at 37°C, 5% CO2. Aliquots of transduced cells were collected on day 3 and 6 for flow cytometry analysis and on day 10, cells were harvested and pelleted for genomic DNA extraction for subsequent Real Time Polymerase Chain Reaction (real time PCR) to determine vector copy number (VCN).
[0117] For spinoculation, cells were resuspended in Stem Span™ SFEM II media containing vector at 10 transducing units (TU) per cell, recombinant human stem cell factor (SCF), thrombopoietin (TPO) and Fms-like tyrosinekinase 3 ligand (FLT3-L) at 100ng/ml each (Stemcell Technologies (Seattle, WA, USA)) and centrifuged at 400g for 1 hour or directly cultured in the presence of LV at 37°C, 5% CO2. Thereafter, the cell pellet was resuspended in the same media and cells were cultured for 24 hours. After 24 hours, cells were harvested and washed by centrifuging at 400g for 5 minutes. Cell pellets were resuspended in Iscove’s Modified Dulbecco’s medium containing 10% v/v heat-inactivated fetal bovine serum and recombinant human stem cell factor (SCF), thrombopoietin (TPO) and Fms-like tyrosinekinase 3 ligand (FLT3-L) at 100ng/ml each (Stemcell Technologies (Seattle, WA, USA)) and cultured for another 9 days at 37°C, 5% CO2. Aliquots of transduced cells were collected on day 3 and 6 for flow cytometry analysis and on day 10, cells were harvested and pelleted for genomic DNA extraction for subsequent Real Time Polymerase Chain Reaction (real time PCR) to determine vector copy number (VCN).
[0118] For MAT, LV were incubated in ViroMag STEM™ at a dilution of 1:500 for 20 minutes (OZ biosciences, France) then added to CD34+ cells in culture media and placed on a CTS™ DynaMag™ magnet (Thermo Fisher Scientific, Waltham, MA) for 30 minutes. The CTS™ DynaMag™ magnet (Thermo Fisher Scientific, Waltham, MA) was set at 0° and the 6-well plate was placed at the center of the magnet. Cells were seeded at 2 x 106, transduced once at 10 transducing units (TU) per cell, and cultured post-transduction in Stem Span™ SFEM II media containing SCF, TPO, and FLT3-L at 100ng/ml each (Stemcell Technologies (Seattle, WA, USA)) for 24 hours. After 24 hours, cells were harvested and washed by centrifuging at 400g for 5 minutes. Cell pellets were resuspended in Iscove’s Modified Dulbecco’s medium containing 10% v/v heat-inactivated fetal bovine serum and recombinant human stem cell factor (SCF), thrombopoietin (TPO) and Fms-like tyrosinekinase 3 ligand (FLT3-L) at 100ng/ml each (Stemcell Technologies (Seattle, WA, USA)) and cultured for another 9 days at 37°C, 5% CO2. Aliquots of transduced cells were collected on day 3 and 6 for flow cytometry analysis and on day 10, cells were harvested and pelleted for genomic DNA extraction for subsequent Real Time Polymerase Chain Reaction (real time PCR) to determine vector copy number (VCN).
[0119] No difference in viability or expression levels of low-density lipoprotein receptor (LDLR), the described receptor for both VSV-G and cocal, was observed across any condition. GFP detected in cells gene modified by cocal LV was 10-60% higher than in cells modified by VSV-G LV. MAT yielded 5-fold higher transduction efficiency in CD34+ cells in comparison to standard culture-based transduction and spinoculation as shown in FIG. 8.
[0120] In all experiments cells were seeded at 2 x10s/ml_, transduced once at 10 transducing units (TU) per cell and cultured post-transduction in Iscove’s Modified Dulbecco’s Medium containing 10% fetal bovine serum and SCF, TPO, and FLT3-L for 9 days.
[0121] No difference in viability or expression levels of low-density lipoprotein receptor (LDLR), the described receptor for both VSV-G and cocal, was observed across any condition. GFP detected in cells gene modified by cocal LV was 10-60% higher than in cells modified by VSV-G LV. MAT yielded 5-fold higher transduction efficiency in CD34+ cells in comparison to standard culture-based transduction and spinoculation.
[0122] EXAMPLE II. In vivo engraftment of MAT-treated cells in NOD/SCID gamma-/- (NSG) immunodeficient juvenile. Primary human hematopoietic stem and progenitor cells (HSPCs, CD34+) from G-CSF mobilized adult donors were slow-thawed at 37°C for 30 minutes. The cells were then stimulated for 16-24 hours at 37°C and 5%CO2 in Stem Span™ SFEM II media containing recombinant human stem cell factor (SCF), thrombopoietin (TPO) and Fms-like tyrosinekinase 3 ligand (FLT3-L) at 50ng/ml each (Stemcell Technologies (Seattle, WA, USA)). LV were incubated in ViroMag STEM™ at a dilution of 1 :500 for 20 minutes (OZ biosciences, France) then added to CD34+ cells in culture media and placed on a CTS™ DynaMag™ magnet (Thermo Fisher Scientific, Waltham, MA) for 30 minutes. The CTS™ DynaMag™ magnet (Thermo Fisher Scientific, Waltham, MA) was set at 0°. The pre-stimulated cells were transduced with a single dose of 10 transducing units of cocal virus envelope glycoprotein pseudotyped LV (cocal LV) per cell.
[0123] Each mouse was injected with 1x106 human HSPCs either freshly transduced or transduced and then cultured in StemSpan™ containing recombinant human stem cell factor (SCF), thrombopoietin (TPO) and Fms-like tyrosinekinase 3 ligand (FLT3-L) at 50ng/ml each (Stemcell Technologies (Seattle, WA, USA)) for2 days. Animals were monitored for any indication of toxicity and human hematopoiesis was evaluated via peripheral blood draws and flow cytometry bi-weekly for a period of 16 weeks after transplant. A necroscopy of bone marrow, spleen, liver and peripheral was performed. Engraftment of genetically modified blood cells was monitored by flow cytometry using a fluorophore-conjugated anti-human CD45 antibody and GFP detection, and by RT-PCR for integrated lentiviral proviral vector sequences (vector copy number; VCN).
Vector integration was assessed by sequencing on the Illumina MiSeq platform. Animal health was monitored by visual inspection and weight monitoring under Good Laboratory Practice (GLP) standards.
[0124] As shown in FIG. 11, mice transplanted with freshly transduced cells had higher levels of engraftment (hCD45+) without transduction effects compared to mice receiving cultured cells (p<0.005). These data suggest that MAT of cocal LV at low doses can greatly reduce viral vector burden.
[0125] Unless otherwise indicated, the practice of the present disclosure can employ conventional techniques of immunology, molecular biology, microbiology, cell biology and recombinant DNA. These methods are described in the following publications. See, e.g., Sambrook, et al. Molecular Cloning: A Laboratory Manual, 2nd Edition (1989); F. M. Ausubel, et al. eds., Current Protocols in Molecular Biology, (1987); the series Methods IN Enzymology (Academic Press, Inc.); M. MacPherson, et al., PCR: A Practical Approach, IRL Press at Oxford University Press (1991); MacPherson et al., eds. PCR 2: Practical Approach, (1995); Harlow and Lane, eds. Antibodies, A Laboratory Manual, (1988); and R. I. Freshney, ed. Animal Cell Culture (1987).
[0126] As will be understood by one of ordinary skill in the art, each embodiment disclosed herein can comprise, consist essentially of, or consist of its particular stated element, step, ingredient, or component. Thus, the terms “include” or “including” should be interpreted to recite: “comprise, consist of, or consist essentially of.” The transition term “comprise” or “comprises” means has, but is not limited to, and allows for the inclusion of unspecified elements, steps, ingredients, or components, even in major amounts. The transitional phrase “consisting of” excludes any element, step, ingredient, or component not specified. The transition phrase “consisting essentially of’ limits the scope of the embodiment to the specified elements, steps, ingredients, or components and to those that do not materially affect the embodiment.
[0127] Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. When further clarity is required, the term “about” has the meaning reasonably ascribed to it by a person skilled in the art when used in conjunction with a stated numerical value
or range, i.e. denoting somewhat more or somewhat less than the stated value or range, to within a range of ±20% of the stated value; ±19% of the stated value; ±18% of the stated value; ±17% of the stated value; ±16% of the stated value; ±15% of the stated value; ±14% of the stated value; ±13% of the stated value; ±12% of the stated value; ±11 % of the stated value; ±10% of the stated value; ±9% of the stated value; ±8% of the stated value; ±7% of the stated value; ±6% of the stated value; ±5% of the stated value; ±4% of the stated value; ±3% of the stated value; ±2% of the stated value; or ±1% of the stated value.
[0128] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0129] The terms “a,” “an,” “the” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
[0130] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
[0131] Certain embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing
description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
[0132] Furthermore, numerous references have been made to patents, printed publications, journal articles and other written text throughout this specification (referenced materials herein). Each of the referenced materials are individually incorporated herein by reference in their entirety for their referenced teaching.
[0133] In closing, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.
[0134] The particulars shown herein are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of various embodiments of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for the fundamental understanding of the invention, the description taken with the drawings and/or examples making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
[0135] Definitions and explanations used in the present disclosure are meant and intended to be controlling in any future construction unless clearly and unambiguously modified in the examples or when application of the meaning renders any construction meaningless or essentially meaningless. In cases where the construction of the term would render it meaningless or essentially meaningless, the definition should be taken from Webster's Dictionary, 3rd Edition, or a dictionary known to those of ordinary skill in the art, such as the Oxford Dictionary of Biochemistry and Molecular Biology (Eds. Attwood T et al., Oxford University Press, Oxford, 2006).
Claims
1. A method comprising: obtaining a cell population comprising target cells, exposing the cell population to target-cell enriching magnetic beads, contacting the target cells with vector-magnetic bead complexes, and applying a magnetic field to the target cells resulting in transduction of the target cells with the vector.
2. The method of claim 1 , wherein the method does not utilize culture media during the transduction.
3. The method of claim 1 , wherein the method does not utilize exogenous cytokines.
4. The method of claim 1 , wherein vector is at an amount of 10 infectious particles per cell in the cell population.
5. The method of claim 1 , wherein vector is at an amount of 10 infectious particles per target cell in the cell population.
6. The method of claim 1 , wherein vector is at an amount of 5-15 infectious particles per cell in the cell population.
7. The method of claim 1 , wherein vector is at an amount of 5-15 infectious particles per target cell in the cell population.
8. The method of claim 1 , wherein the magnetic field is applied for 5-45 minutes.
9. The method of claim 1 , wherein the magnetic field is applied for 15-35 minutes.
10. The method of claim 1 , wherein the magnetic field is applied for 30 minutes.
11. The method of claim 1 , wherein timing of the exposing, contacting, and applying overlaps.
12. The method of claim 1 , wherein the exposing occurs before the contacting and applying.
13. The method of claim 1 , wherein the obtaining the cell population comprises collecting blood or bone marrow.
14. The method of claim 1 , further comprising administering a mobilizer to a subject before the obtaining.
15. The method of claim 14, wherein the mobilizer includes granulocyte colony stimulating factor (G-CSF).
16. The method of claim 1 , wherein the target cells comprise stem cells.
17. The method of claim 16, wherein the stem cells comprise hematopoietic stem cells.
18. The method of claim 1 , wherein the target cells comprise immune cells.
19. The method of claim 18, wherein the immune cells comprise T cells or B cells.
The method of claim 1, wherein the target-cell enriching magnetic beads comprise a magnetic bead and a binding domain that binds the target cells. The method of claim 1 , wherein the vector-magnetic bead complexes comprise a magnetic bead and a vector. The method of claim 21 , wherein the vector comprises a viral vector. The method of claim 22, wherein the viral vector comprises a lentiviral vector. The method of claim 1 , further comprising formulating a cell product for administration to a subject after the applying. The method of claim 24, further comprising evaluating quality and sterility of the cell product. The method of claim 24, further comprising administering the cell product to the subject. The method of claim 26, wherein the subject was administered a mobilizer within 48 hours of the administering of the cell product. The method of claim 26, wherein the subject was administered a mobilizing agent within 48 hours of the administering of the cell product. The method of claim 1 , wherein the method is performed in an International Standards Organization (ISO) level 7 clean room. A method of providing ex vivo gene therapy to a subject in need thereof comprising: collecting a cell population from the subject wherein the cell population includes target cells, enriching the target cells in the cell population by exposing the cell population to targetcell enriching magnetic beads, applying a magnetic field to the cell population in the presence of vector-magnetic bead complexes thereby transducing the target cells, and formulating and administering transduced target cells to the subject. The method of claim 30, wherein the subject does not receive chemotherapy between the collecting and the administering. The method of claim 30, wherein the method does not utilize culture media during the transducing. The method of claim 30, wherein the method does not utilize exogenous cytokines during the transducing. The method of claim 30, wherein vector is at an amount of 10 infectious particles per cell in the cell population. The method of claim 30, wherein vector is at an amount of 10 infectious particles per target
cell in the cell population. The method of claim 30, wherein vector is at an amount of 5-15 infectious particles per cell in the cell population. The method of claim 30, wherein vector is at an amount of 5-15 infectious particles per target cell in the cell population. The method of claim 30, wherein the magnetic field is applied for 5-45 minutes. The method of claim 30, wherein the magnetic field is applied for 15-35 minutes. The method of claim 30, wherein the magnetic field is applied for 30 minutes. The method of claim 30, wherein timing of the exposing and applying overlaps. The method of claim 30, wherein the exposing occurs before the applying. The method of claim 30, wherein the collecting the cell population comprises collecting blood or bone marrow. The method of claim 30, further comprising administering a mobilizer to the subject before the collecting. The method of claim 44, wherein the mobilizer comprises granulocyte colony stimulating factor (G-CSF). The method of claim 44, wherein the transduced target cells and the mobilizer are administered within 48 hours of each other. The method of claim 44, wherein the transduced target cells and the mobilizer are administered within 24 hours of each other. The method of claim 30, wherein the exposing, applying, and formulating occur in an International Standards Organization (ISO) level 7 clean room. The method of claim 30, wherein the target cells comprise stem cells. The method of claim 49, wherein the stem cells comprise hematopoietic stem cells. The method of claim 30, wherein the target cells comprise immune cells. The method of claim 51 , wherein the immune cells comprise T cells or B cells. The method of claim 30, wherein the target-cell enriching magnetic beads comprise a magnetic bead and a binding domain that binds the target cells. The method of claim 30, wherein the vector-magnetic bead complexes comprise a magnetic bead linked to a vector. The method of claim 54, wherein the vector comprises a viral vector. The method of claim 55, wherein the viral vector comprises a lentiviral vector. The method of claim 30, further comprising harvesting and washing transduced target cells.
The method of claim 30, further comprising release testing of transduced target cells. The method of claim 30, wherein there is no more than 24 hours between the collecting and the administering. An apparatus comprising a docking unit, an entry port, and a magnet, wherein the docking unit comprises an interface between the apparatus and a cell collection and/or manufacturing system.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263379885P | 2022-10-17 | 2022-10-17 | |
US63/379,885 | 2022-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024086595A2 true WO2024086595A2 (en) | 2024-04-25 |
Family
ID=90738499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/077110 WO2024086595A2 (en) | 2022-10-17 | 2023-10-17 | Systems and methods for gene therapy |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024086595A2 (en) |
-
2023
- 2023-10-17 WO PCT/US2023/077110 patent/WO2024086595A2/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10828333B2 (en) | Point-of-care and/or portable platform for gene therapy | |
JP6970106B2 (en) | VCS Enhancer Composition and How to Use It | |
JP2008539796A (en) | Transduction of primary cells | |
US20220025403A1 (en) | Reduced and minimal manipulation manufacturing of genetically-modified cells | |
US20230279441A1 (en) | Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies | |
JP2022530130A (en) | Buffer composition containing enucleated red blood cells | |
Donahue et al. | Large animal models for stem and progenitor cell analysis | |
US20200199534A1 (en) | Therapeutic formulations containing cd34+ stem cells derived from negative selection | |
JP4552056B2 (en) | How to acquire acquired immune tolerance | |
WO2024086595A2 (en) | Systems and methods for gene therapy | |
US11155833B2 (en) | Method for producing transgenic cell | |
Clapp et al. | The use of umbilical cord blood as a cellular source for correction of genetic diseases affecting the hematopoietic system | |
Jung et al. | Hematopoietic stem cell engraftment: a direct comparison between intramarrow and intravenous injection in nonhuman primates | |
Donahue et al. | Sources and methods for obtaining stem and progenitor cells | |
Watts et al. | No evidence of clonal dominance after transplant of HOXB4-expanded cord blood cells in a nonhuman primate model | |
JP2023521052A (en) | Improving viral transduction efficiency | |
Castellino et al. | Retroviral vector-mediated gene transfer into umbilical cord blood-derived megakaryocyte and platelet progenitors | |
Base | NOVEL APPROACHES OR HEMATOPOIETIC GENE THERAPY | |
Roselli et al. | HEMATOPOIETIC DISORDERS | |
d Johnston et al. | development of a highly efficient lentiviral gene transfer protocol for hematopoietic stem cells | |
Péault et al. | Gene transfer into human haematopoietic stem cells | |
Mostoslavsky et al. | 274. Lentiviral Gene Transfer into Hematopoietic Stem Cells: Getting the Best out of It | |
Bellantuono et al. | Adult Stem Cells and Gene Therapy | |
Tran | In utero gene transfer into fetal sheep: A large animal model for in utero gene therapy | |
de Sio et al. | HEMATOPOIETIC STEM CELL GENE TRANSFER: LBNT1 VIRUS VECTORS |